WO2010072831A1 - Sulfurizing reagents and their use for oligonucleotides synthesis - Google Patents

Sulfurizing reagents and their use for oligonucleotides synthesis Download PDF

Info

Publication number
WO2010072831A1
WO2010072831A1 PCT/EP2009/067902 EP2009067902W WO2010072831A1 WO 2010072831 A1 WO2010072831 A1 WO 2010072831A1 EP 2009067902 W EP2009067902 W EP 2009067902W WO 2010072831 A1 WO2010072831 A1 WO 2010072831A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
oligonucleotide
mmol
mixture
formula
Prior art date
Application number
PCT/EP2009/067902
Other languages
French (fr)
Inventor
Wieslaw Adam Mazur
Yigang He
Victor Sorokin
Original Assignee
Girindus America, Inc
Girindus Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Girindus America, Inc, Girindus Ag filed Critical Girindus America, Inc
Priority to CN2009801552887A priority Critical patent/CN102307889A/en
Priority to CA2747999A priority patent/CA2747999A1/en
Priority to JP2011542834A priority patent/JP2012513450A/en
Priority to EP09799643A priority patent/EP2382227A1/en
Publication of WO2010072831A1 publication Critical patent/WO2010072831A1/en
Priority to US13/165,918 priority patent/US20120071640A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/08Sulfenic acids; Derivatives thereof
    • C07C313/18Sulfenamides
    • C07C313/36Sulfenamides having nitrogen atoms of sulfenamide groups further bound to other hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48Sulfur atoms

Definitions

  • the present application claims the benefit of U.S. application No. 61/140391, filed December 23, 2008, the whole content of which being herein incorporated by reference.
  • Technical Field The present invention relates to phosphorothioate oligonucleotides, the preparation thereof using novel sulfurizing reagents, said sulfurizing reagents and the preparation thereof.
  • Oligonucleotides belong to a class of biopharmaceuticals with a great potential for therapies of various diseases including cancer, viral infections and inflammatory disease to name a few.
  • An important approach to advancing oligonucleotides as therapeutics involve modifications of the oligomer backbone to provide, among other things, metabolic resistance, chemical stability and to improve in vivo transport to the site of action. Examples of modified backbone chemistries include: peptide nucleic acids (PNAs) (see Nielsen, Methods MoI.
  • Phosphorothioates can be formed by oxidative sulfurization (Oligonucleotide synthesis, methods and applications, P. Herdewijn Methods in Molecular Biology, volume 288, Chapter 4, 51-63). There are basically two approaches to making phosphorothioates depend upon the nature of phosphorous esters used for this reaction and the expected products. One of them involves introduction of the unsubstituted sulfur atom to phosphorus by means of, for example, elemental sulfur, dibenzoyl tetrasulfide, 3-H-l,2- benzodithiol-3-one 1,1 -dioxide (also known as Beaucage reagent, (Iyer et al., J. Org. Chem.
  • TETD tetraethylthiuram disulfide
  • DTD dimethylthiuram disulfide
  • PADS phenylacetyl disulfide
  • Stec's reagent bis(O,O-diisopropoxy phosphinothioyl) disulfide
  • a second approach to making oligomeric phosphorothioates is used with the H-phosphonate method and involves a reaction between H- phosphonate diester and a sulfur transfer reagent in which the sulfur atom, bearing an aliphatic or aromatic substituent, is transferred to phosphorus.
  • the auxiliary substituent at sulfur serves the role of a protecting group during the synthetic operation and usually is cleaved at the final stage of oligonucleotide preparation. This method is particularly suitable for the synthesis of oligonucleotides in solution.
  • a critical problem in the solution synthesis of oligonucleotides concerns the necessity to obtain high substrate conversions with excellent specificity at each synthetic step giving high purity products in a form that facilitates simple purification, in particular avoiding chromatography. Given the lack of methods allowing for economical solution phase synthesis, the solution phase technology does not seem to be currently used for commercial scale oligonucleotide synthesis.
  • the invention now discloses novel sulfurizing reagents, a process for their manufacture and their use in the economical and convenient synthesis and purification of phosphorothioate oligonucleotides notably in solution. Disclosure of Invention
  • the present invention relates in particular to the invention described in the appended claims.
  • the invention also relates to processes and reagents substantially described in the present specification, in particular in the examples.
  • the invention has a number of advantages over existing methods of P-S linkage formation, in particular in the synthesis of oligonucleotides carried out preferably via the H-phosphonate method.
  • the residue R transferred e.g. to an oligonucleotide with the novel reagent can facilitate crystallization or precipitation of oligonucleotides, allowing for simple purification of the products with minimum or no chromatography. It has been found out that the oligonucleotides having from two to at least sixteen nucleotide units made with this method do not necessarily have to be purified by chromatography until after the final deprotection of the required oligonucleotide.
  • the intermediate oligomers can be obtained pure enough for optional deprotections at the 5'- and 3' - positions and further coupling of these crude deprotected materials to higher oligonucleotides, if desired.
  • the disclosed method provides an access to a variety of sulfurizing reagents which can be used to modify the properties of formed oligonucleotides with respect to maximizing the efficiency of simple, chromatography- free purifications.
  • Still another advantage of the method according to the invention is that a simple cleavage of for example the sulfur- protecting acyloxymethylene group RC(O)-OCH 2 can be easily accomplished under mild conditions, for example, with primary or secondary or hindered amines e.g.
  • cleavage products can be easily removed from the products by solvent or aqueous wash.
  • the stability characteristics for example of the acyloxymethylene group e.g. under basic non-nucleophilic conditions allow for selective deprotection reactions along the synthesis pathways and hence greater flexibility of synthesis schemes, for example by preventing the cleavage of nucleobase protection groups.
  • each elongation cycle comprises generally three steps and it is advantageous to remove even small amounts of impurities which would otherwise accumulate along the way. Because of large number of steps, the use of chromatography at each step may not be economically feasible in the practical large scale oligonucleotide synthesis. Therefore, we also disclose a chromatography- free methodology for the purification of oligonucleotides formed during the chain elongation process.
  • a first particular object of this invention is to provide oligonucleotides which comprise at least one internucleotide linkage comprising a P-S-R bond and at least two nucleosides, wherein R corresponds to the formula (I)
  • A is a geminally substituted alkylene group, preferably CH 2
  • X and Y are independently selected from S and O
  • Ro is selected from the group consisting of optionally substituted carbon bonded organic residue, such as in particular optionally substituted alkyl or aryl, SRx, ORx and NRxRy wherein Rx and Ry are selected from H and organic residues and at least Rx is a substituent other than H.
  • the oligonucleotides according to the invention are valuable synthesis intermediates for synthesis of P-sulfurized oligonucleotides which have advantageous properties as to their solubility characteristics thus allowing for efficient purification which can be effectively accomplished, for example, by a combination of precipitation and extraction techniques.
  • the oligonucleotides according to the invention are also believed to be effective as pro-drug, capable to release a phosphorothioate oligonucleotide in vivo, by cleavage of the R-group in the human body or in the body of an animal.
  • oligonucleotide in the frame of the present invention, denotes in particular an oligomer of nucleoside monomeric units comprising sugar units connected to nucleobases, said nucleoside monomeric units being connected by internucleotide bonds.
  • An "internucleotide bond” refers in particular to a chemical linkage between two nucleoside moieties, such as the phosphodiester linkage typically present in nucleic acids found in nature, or other linkages typically present in synthetic nucleic acids and nucleic acid analogues.
  • Such internucleotide bond may for example include a phospho or phosphite group, and may include linkages where one or more oxygen atoms of the phospho or phosphite group are either modified with a substituent or replaced with another atom, e.g., a sulfur atom, or the nitrogen atom of a mono- or di-alkyl amino group.
  • Typical internucleotide bonds are diesters of phosphoric acid or its derivatives, for example phosphates, thiophosphates, dithiophosphate, phosphoramidates, thio phosphoramidates.
  • nucleoside is understood to denote in particular a compound consisting of a nucleobase connected to a sugar.
  • Sugars include, but are not limited to, furanose ring such as ribose, 2'-deoxyribose and non-furanose ring such as cyclohexenyl, anhydrohexitol, morpholino.
  • the modifications, substitutions and positions indicated hereinafter of the sugar included in the nucleoside are discussed with reference to a furanose ring, but the same modifications and positions also apply to analogous positions of other sugar rings.
  • the sugar may be additionally modified. As non limitative examples of the modifications of the sugar mention can be notably made of modifications at e.g.
  • the 2'-or 3'-position, in particular 2'-position of a furanosyl sugar ring including for instance hydrogen; hydroxy; alkoxy such as methoxy, ethoxy, allyloxy, isopropoxy, butoxy, isobutoxy, methoxyethyl, alkoxy, phenoxy; azido; amino; alkylamino; fluoro; chloro and bromo; 2 '-4'- and 3 '-4 '-linked furanosyl sugar ring modifications, modifications in the furanosyl sugar ring including for instance substitutions for ring 4'-0 by S, CH 2 , NR, CHF or CF 2 .
  • nucleobase is understood to denote in particular a nitrogen- containing heterocyclic moiety capable of pairing with a, in particular complementary, nucleobase or nucleobase analog.
  • Typical nucleobases are the naturally occurring nucleobases including the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U), and modified nucleobases including other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil
  • nucleobases include tricyclic pyrimidines such as phenoxazine cytidine(lH-pyrimido[5,4- b][l,4]benzoxazin-2(3H)-one), phenothiazine cytidine (lH-pyrimido[5,4- b][l,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g.
  • Oligonucleotide typically refers to a nucleoside subunit polymer having from about 2 to about 50 contiguous subunits. The nucleoside subunits can be joined by a variety of intersubunit linkages.
  • oligonucleotides includes modifications, known to one skilled in the art, to the sugar backbone (e.g., phosphoramidate, phosphorodithioate), the sugar (e.g., 2' substitutions such as 2'-F, 2'-0Me), the base, and the 3' and 5' termini.
  • the oligonucleotide comprises from 2 to 30 nucleotides.
  • the oligonucleotide contains nucleosides selected from ribonucleosides, 2'-deoxyribonucleosides, 2 '-substituted ribonucleosides, 2'-4'-locked-ribonucleosides, 3 '-amino- ribonucleosides, 3'- amino-2'-deoxyribonucleosides.
  • R is selected from a methyleneacyloxy group, a methylene carbonate group and a methylene carbamate group.
  • R is a methyleneacyloxy group, it corresponds preferably to formula -CH 2 -O-C(O)-Ro wherein R 0 is a C1-C20, saturated, unsaturated, heterocyclic or aromatic, hydrocarbon residue.
  • Ro is a saturated hydrocarbon residue, it is preferably selected from linear, branched or cyclic alkyl residues. Ro can for example be selected from lower alkyl or cycloalkyl (C1-C7) residues. Particular saturated hydrocarbon residues are selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert. butyl, cyclopentyl and cyclohexyl.
  • a methyl, ethyl or n-propyl group is preferred.
  • An ethyl group is more particularly preferred.
  • Ro is an aromatic residue, it is suitably selected from aromatic systems having from 6 to 14 carbon atoms.
  • Particular aromatic residues are selected from phenyl and naphthyl groups which can be substituted, for example, by aryl or heteroaryl, alkyl, cycloalkyl, heterocycle or heterosubstitutents such as halogens,amines,ethers, carboxylates, nitro, thiols, sulfonic and sulfones.
  • a phenyl group is preferred.
  • Ro is a heterocyclic residue
  • it is often selected from heterocycles containing at least one annular N, O or S atom which are bonded to the carbonyl group through an annular carbon atom.
  • heterocyclic residues include pyridine and furan.
  • the oligonucleotide comprises at least two internucleotide linkages comprising a P-S-R bond and at least three nucleotides, wherein R is a methyleneacyloxy group as described herein.
  • R is a methylene carbamate group
  • Rx and Ry are independently selected from alkyl or (hetero)aryl.
  • Rx and/or Ry are alkyl groups.
  • Rx and/or Ry can for example be selected from lower alkyl or cycloalkyl (C1-C7) residues.
  • Particular alkyl groups are selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert butyl, cyclopentyl and cyclohexyl.
  • Rx and Ry in the methylene carbamate group are both alkyl groups, in particular as described herein before.
  • a N,N-dimethyl or N 5 N- diethyl group is more particularly preferred.
  • R x and Ry form together a 3 to 8 membered ring optionally containing an additional annular heteroatom selected from O, N and S.
  • Particular examples include a N-piperidyl or an N-pyrrolidyl group.
  • R is a methylene carbonate group, it corresponds preferably to formula -CH 2 -O-C(O) ORx wherein Rx is selected from optionally substituted alkyl, cycloalkyl and (hetero)aryl groups.
  • Rx is an alkyl group.
  • Rx can for example be selected from lower alkyl or cycloalkyl (C1-C7) residues.
  • Particular alkyl groups are selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert butyl, cyclopentyl and cyclohexyl.
  • a methyl, ethyl or n-propyl group is preferred.
  • An ethyl group is more particularly preferred.
  • Rx is an aryl group, it is suitably selected from aromatic systems having from 6 to 14 carbon atoms. Particular aromatic residues are selected from phenyl and naphthyl groups. A phenyl group is preferred.
  • Rx is a heterocyclic residue, it is often selected from heterocycles containing at least one annular N, O or S atom which are bonded to the oxycarbonyl group through an annular carbon atom. Particular examples of such heterocyclic residues include pyridine and furan.
  • substituents Rx, Ry and Ro given herein before for the case when R is selected from methyleneacyloxy group, a methylene carbonate group and a methylene carbamate group equally apply to the corresponding thioanalogues wherein X and/or Y in formula (I) are sulfur. It is also understood that the mentioned substituents may be optionally substituted, for example by halogen or alkoxy substituents or they may be modified, for example by inclusion of catenary heteroatoms, in particular oxygen into an alkyl chain.
  • a second particular object of this invention relates to a sulfurizing agent of formula R"-S-R wherein R is as defined here before in the context of the oligonucleotide according to the invention and R" is a leaving group.
  • the sulfurization agent according to the invention allows for particularly efficient sulfur transfer, in particular to form S- protected phosphorthioate internucleotide linkages in oligonucleotides.
  • the sulfurizing agent according to the invention introduces a protected sulfur from which the protective group can be cleaved selectively and efficiently.
  • the leaving group R" is generally an electrophilic group.
  • R" is a group containing an electrophilic nitrogen atom bonded to the sulfur.
  • the electrophilic nitrogen atom is suitably substituted with at least one electron- withdrawing group.
  • the sulfurizing agent corresponds to formula (II)
  • R A R-S'%° wherein R A and R B are equal or different from each other and at least one of R A and R B is selected from substituted sulfonyl or an acyl group, said R A and R B optionally forming together a cyclic substituent.
  • R A and R B When at least one, preferably one, of R A and R B is substituted sulfonyl, it is generally selected from alkyl and aryl sulfonyl groups.
  • the alkyl substituent therein is preferably selected from lower alkyl or cycloalkyl (C1-C7) residues.
  • Particular alkyl groups are selected from methyl, ethyl, n-propyl, isopropyl, n- butyl, sec-butyl, tert-Butyl, cyclopentyl and cyclohexyl.
  • a methyl, ethyl or n- propyl group is preferred.
  • a methyl group is more particularly preferred.
  • the aryl substituent therein is, for example, an, optionally substituted, phenyl group.
  • the alkyl substituent therein is preferably selected from lower alkyl or cycloalkyl (C1-C7) residues.
  • alkyl groups are selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert butyl, cyclopentyl and cyclohexyl.
  • a methyl, ethyl or n-propyl group is preferred.
  • a methyl group is more particularly preferred.
  • R A and R B are acyl groups forming together a cyclic substituent, preferably a 4 to 7 membered ring
  • the sulfurizing agent corresponds to formula (III)
  • Ri, R 3 and R 4 are independently a C1-C20, optionally unsaturated or aromatic, hydrocarbon residue, preferably a linear or branched alkyl group or a cycloalkyl group.
  • R" is a dicarboxylamide.
  • the sulfurizing agent corresponds to formula (IV)
  • Z is an group, chosen among the group of -CH 2 -CH 2 - ,
  • a third particular object of the invention relates to a process for the synthesis of the sulfurizing agent according to the invention which comprises (a) reacting a sulfuryl halide, preferably sulfuryl chloride with a thioacetal of formula R-S-C(O)-R 2 wherein R is as described previously and R 2 is an organic residue, preferably selected from a C1-C20 optionally unsaturated or aromatic hydrocarbon residue to produce an intermediate product of formula R-S-W, wherein W is halogen preferably Cl and, (b) reacting said intermediate product with an N-sulfonyl compound or an N-acyl compound.
  • the thioacetal is of formula Ri- C(O)-O-CH 2 -S-C(O)-R 2 wherein Ri and R 2 are independently a C1-C20 optionally unsaturated or aromatic hydrocarbon residue and said thioacetal is reacted with sulfuryl chloride to produce an intermediate product of formula Ri-C(O)-O-CH 2 -S-Cl, wherein Ri is independently a C1-C20, optionally unsaturated or aromatic, hydrocarbon residue.
  • step (b) the intermediate is reacted with an N-sulfonyl compound of formula R 3 -S (O) 2 -NH-R 4 , wherein R 3 and R 4 are independently organic residues, preferably a C1-C20, optionally unsaturated or aromatic, hydrocarbon residue .
  • the reaction of step (a) is generally carried out in an aprotic polar organic solvent such as for example a halogenated hydrocarbon solvent, in particular a chlorinated hydrocarbon solvent such as methylene chloride.
  • the reaction of step (a) is generally carried out at a temperature of from -8O 0 C to 30 0 C.
  • step (b) the reaction of step (b) is generally carried out in an aprotic polar organic solvent such as for example a halogenated hydrocarbon solvent, in particular a chlorinated hydrocarbon solvent such as methylene chloride.
  • an aprotic polar organic solvent such as for example a halogenated hydrocarbon solvent, in particular a chlorinated hydrocarbon solvent such as methylene chloride.
  • step (b) the reaction of step (b) is generally carried out at a temperature of from -20 0 C to 50 0 C, preferably from 0 0 C to 30 0 C.
  • a fourth particular object of this invention concerns a method for manufacturing an oligonucleotide using the sulfurizing agent according to the invention.
  • the method according to the invention comprises at least (a) a coupling step wherein a phosphorus internucleotide linkage is formed between two reactants selected from nucleotides and oligonucleotides and (b) a sulfurization step wherein the sulfurizing agent according to the invention is used to sulfurize said phosphorus internucleotide linkage.
  • Steps (a) and (b) can be repeated after 3' or 5' deprotection of the sulfurized oligonucleotide.
  • Step (a) of said manufacturing method preferably comprises forming the H-phosphonate diester bond by coupling an H-phosphonate monoester salt with a protected nucleoside or oligonucleotide having a free hydroxy group. The coupling is preferably carried out in solution phase.
  • Step (a) is preferably carried out in an aprotic polar organic solvent for example a halogenated solvent or nitrogen containing solvents, more particularly N-heterocyclic solvents or chlorinated hydrocarbon, even more particularly acetonitrile and pyridine and preferably pyridine.
  • the reaction to form an H-Phosphonate diester is preferably activated by a carboxylic acid halide, in particular pivaloyl chloride.
  • Step (a) is generally carried out at a temperature from -40 0 C to 30 0 C, preferably from 0 0 C to 20 0 C .
  • the liquid reaction medium generally contains at least 20% by weight of H-phosphonate oligonucleotide relative to the total weight of the reaction medium. Preferably this content is at least 20% weight.
  • the liquid reaction medium generally contains at most 50% by weight of H- phosphonate oligonucleotide relative to the total weight of the reaction medium.
  • step (a) may be isolated and subsequently sulfurized in step (b). It may also, preferably, be used without isolation in step (b). Sulfurization of formed diester can be carried by in-situ addition of the sulfurizing reagent, suitably dissolved in an appropriate solvent, or after pre-purifying formed diester from the reaction mixture.
  • Step (b) is preferably carried out in an aprotic polar organic solvent such as for example a solvent comprising a halogenated hydrocarbon solvent, in particular a chlorinated hydrocarbon solvent such as methylene chloride.
  • step (b) is carried out in a solvent mixture comprising a halogenated hydrocarbon solvent and nitrogen containing solvents, more particularly N-heterocyclic solvents, preferably pyridine.
  • a pyridine/methylene chloride mixture is more particularly preferred, in particular when the coupling product of step (a) is sulfurized without isolation.
  • Step (b) is generally carried out at a temperature of from -40 0 C to 30 0 C, preferably from 0 0 C to 20 0 C.
  • the molar ratio of sulfurizing agent relative to the amount of internucleotide linkages to be sulfurized is generally at least 1, often from 1.5 to 4.0, preferably from 2.0 to 3.0.
  • the intermediate H-phosphonate diester is preferably activated by by an activator, in particular a base.
  • Suitable bases include alkylamines, in particular tertiary alkylamines, diisopropylethylamine is preferred.
  • the invention in a fifth aspect, relates to a method for purifying an oligonucleotide in accordance with the invention having at least one P-S-R linkage as described herein before.
  • the method comprises at least precipitating the second oligonucleotide.
  • this method further comprise extraction of the second oligonucleotide, in particular from solid material recovered from the precipitation step, with a solvent.
  • Suitable solvents for extraction include a polar organic solvent
  • the precipitation method generally comprises (a) dissolving the oligonucleotide in a polar organic solvent and (b) adding a non-polar organic solvent until the solution becomes turbid.
  • the solvent used to dissolve the oligonucleotide in step (a) is preferably selected from halogenated hydrocarbons such as methylene chloride and chloroform, nitrogen containing solvents such as acetonitrile and pyridine, and carbonyl-containing solvents such as acetone.
  • a solvent volume is used ranging from about 0.5 (n+1) mL to about 2.0 (n+1) mL. Preferably, about 1.0 (n+1) niL, where n is the millimoles number of phosphorothioate triester linkages.
  • the solution of the second oligonucleotide is treated with a non-polar organic solvent preferably selected from hydrocarbons, for example alkane solvents such as hexane, ether solvent in particular MTBE and their mixtures, such as, preferably hexane/MTBE mixtures until the solution becomes turbid.
  • a non-polar organic solvent preferably selected from hydrocarbons, for example alkane solvents such as hexane, ether solvent in particular MTBE and their mixtures, such as, preferably hexane/MTBE mixtures until the solution becomes turbid.
  • the turbid solution is subsequently treated with a precipitation aid.
  • the precipitation aid is generally selected from inert porous solids preferably selected from Celite, charcoal, wood cellulose and chromatography stationary phases such as silica or alumina.
  • the precipitation aid is generally used in an amount ranging from about 0.25 (n+1) g to about 1.5 (n+1) g, preferably, about 0.75 (n+1) g, where n is the millimoles number of phosphorothioate triester linkages.
  • the mixture is treated with a second fraction of a non-polar organic solvent as described here before.
  • the volume of said fraction generally ranges from about l(n+l) mL to about 4(n+l) mL, preferably, about 2.0 (n+1) mL, wherein n is the millimoles number of phosphorothioate triester linkages.
  • the obtained mixture is generally subjected to a solid/liquid separation operation such as, preferably, a filtration.
  • a solid/liquid separation operation such as, preferably, a filtration.
  • the oligonucleotide is generally recovered from solid recovered from solid/liquid separation operation, in particular from precipitation aid by extraction with a polar organic solvent preferably selected from carbonyl-type solvents such as acetone, from nitrogen-containing solvents such as acetonitrile and from halogenated hydrocarbons such as methylene chloride and chloroform.
  • the oligonucleotide obtained from the above precipitation treatment can be further purified by partitioning between an organic solvent and water. This step usually separates polar impurities, which dissolve in aqueous layer, from the product.
  • the oligonucleotide is suitably dissolved in a organic solvent, in particular a polar organic solvent such as nitrogen- containing solvents in particular selected from acetonitrile, formamides such as DMF and N-hetero cycles such as pyridine, carbonyl-type solvents such as acetone, or THF or DMSO.
  • the volume of organic solvent used is generally ranging from 2.0 (n+1) mL to 8.0 (n+1) mL, preferably, about 4.0 (n+1) mL, where n is the millimoles number of the phosphorothioate triester linkage.
  • the solution is treated with an aqueous medium, in particular water.
  • the volume of aqueous medium used is generally from about 0.5 volume equivalent of the organic solvent to about 1.5 volume equivalent of the organic solvent, usually about 0.7 volume equivalent of the organic solvent.
  • an oligonucleotide-containing layer is generally separated and can be further processed, if appropriate, to obtain purified oligonucleotide.
  • a sixth particular object of this invention concerns a method for producing a second oligonucleotide having at least one phosphothioate group, which comprises (a) providing a first oligonucleotide according to the invention and (b) cleaving at least one R group, from said first oligonucleotide to produce said second oligonucleotide having at least one thiophosphate linkage.
  • the R group is cleaved by reacting the first oligonucleotide in solution with a base chosen preferably from alkyl, cycloalkyl and aromatic amines, more preferably from primary, for example an alkyl primary amine wherein alkyl group bears identical or different substituents selected preferably from Cl to C8 linear or branched alkyl or secondary alkyl amines, most preferably from n-propyl and tert-butyl amine, preferably the base is a hindered primary amine.
  • a base chosen preferably from alkyl, cycloalkyl and aromatic amines, more preferably from primary, for example an alkyl primary amine wherein alkyl group bears identical or different substituents selected preferably from Cl to C8 linear or branched alkyl or secondary alkyl amines, most preferably from n-propyl and tert-butyl amine, preferably the base is a hindered primary amine.
  • the cleavage according to the sixth aspect of the invention is carried out in the presence of a sterically hindered base and of an activator which is generally a N-heteroaromatic base.
  • activator is 1,2,4-triazole or other triazole and tetrazole derivatives, and more preferably such activator is used with a sterically hindered base, in particular tert-butyl amine.
  • the deprotection of S-methylene-ester, -carbonate or -carbamate group can be accomplished for example in a treatment of protected nucleotide with a sterically hindered base such as e.g. t-butylamine.
  • a sterically hindered base such as e.g. t-butylamine.
  • These bulky amines are particularly selective because they do not react with the nucleobases, particularly those protected at carbonyl oxygen. They allow in fact limiting or substantially avoiding possible side-reactions with the nucleobase moiety.
  • an activator may suitably be added.
  • activators which are suitable include N- heterocyclic bases such as e.g. diazole, triazole, and their derivatives. This embodiment allows particularly clean, fast and efficient deprotection reactions.
  • the deprotection method involves using a substituted aniline as base wherein the aryl group of the aniline contains linear or branched alkyl or aryl substituents at 2 and/or 6 positions such as e.g. 2,6-dimethylaniline and 2,6-diethylaniline.
  • the deprotection according to the sixth aspect is preferably carried out in an aprotic polar organic solvent for example a solvent comprising nitrogen containing solvents, more particularly N-heterocyclic solvents, preferably pyridine.
  • an aprotic polar organic solvent for example a solvent comprising nitrogen containing solvents, more particularly N-heterocyclic solvents, preferably pyridine.
  • the deprotection according to the sixth aspect is generally carried out at a temperature from -10 0 C to 50 0 C, preferably from 0 0 C to 30 0 C.
  • the liquid reaction medium generally contains at least 20% by weight of first oligonucleotide relative to the total weight of the reaction medium. Preferably this content is at least 50% weight.
  • the amount of base used is generally ranging from 5n mmol to 15n mmol, preferably about 1On mmol, where n is the millimoles number of the phosphorothioate triester linkage.
  • the amount of activator used is generally ranging from 0.5n mmol to 3n mmol, preferably, 1.5n mmol, where n is the millimoles number of the phosphorothioate triester linkage.
  • Ap, Gp, Tp are the 2-deoxyribose nucleobases as previous described respectively connected to A, G and T nucleobases as previously described wherein A, G and T are protected as follows: Ap is the 2-deoxyribose nucleobase wherein A is N-(purin-6- yl)benzamide, Gp is the 2-deoxyribose nucleobase wherein G is N-(6-(2,5- dichlorophenoxy)-purin-2-yl)isobutyramide and Tp is the nucleobase wherein T is 5-methyl-4-phenoxypyrimidin-2-one.
  • Ap(S), Gp(S) and Tp(S) are the corresponding 4'0-P-thiomethyl propionates of respectively Ap, Gp and Tp as previously described.
  • Ap(H), Gp(H) and Tp(H) are the corresponding 4'0-P-H phophonates of respectively Ap, Gp and Tp as previously described.
  • DMTr is the bis para-methoxy trityl protecting group, known to one skilled in the art, bonded to the 5-0' of the corresponding oligonucleotide as previously described, when linked to it.
  • Lev is the pentanl,4-dione protecting group, known to one skilled in the art, bonded to the 3-0' of the corresponding oligonucleotide as previously described, when linked to it.
  • Methanesulfonyl chloride 38.7 mL, 500 mmol was added dropwise over 15 min to stirred aqueous methylamine (40% in water, 152 mL,
  • N-methyl methanesulfonamide (1.09 g, 10.0 mmol)
  • pyridine (1.66 g, 21.0 mmol)
  • bis(propionyloxymethyl)disulfide 1.2 g, 5.0 mmol
  • anhydrous CH 2 Cl 2 8 mL
  • the mixture was stirred under N 2 at room temperature and a solution ofBr 2 (0.882 g, 5.52 mmol) in 4 mL Of CH 2 Cl 2 was added dropwise over 30 min.
  • the resulting mixture was stirred at room temperature for 2 hours.
  • MTBE (15 mL) was added and the resulting mixture was filtered.
  • N-methyl methanesulfonamide (49.5 g, 453.1 mmol)
  • molecular sieves (4 A, activated, 5.0 g)
  • anhydrous CH 2 Cl 2 200 mL
  • anhydrous pyridine 41.9 mL, 517.8 mmol
  • the above solution A was added slowly over 15 minutes.
  • the resulting mixture was then stirred at room temperature for 1.5 hours.
  • Hexane 200 mL was added slowly and the resulting mixture was stirred at room temperature for 10 minutes.
  • chloromethyl chloroformate (12.9 g, 100.0 mmol), anhydrous acetonitrile (300 mL).
  • the solution is stirred in an ice-water bath, and a mixture of anhydrous ethanol (4.6 g, 100.0 mmol) and anhydrous pyridine (23.7 g, 300 mmol) is added slowly over 20 min.
  • the mixture is stirred at room temperature for 1 hour.
  • Sodium iodide (1.50 g, 10.0 mmol) is added into the reaction mixture.
  • the mixture is stirred in an ice-water bath, and thioacetic acid (7.6 g, 100 mmol) is added over 5 min.
  • N-methyl methanesulfonamide (6.0 g, 55.0 mmol), molecular sieves (4 A, activated, 3.0 g) and anhydrous CH 2 Cl 2 (150 mL).
  • N-methyl methanesulfonamide 6.0 g, 55.0 mmol
  • molecular sieves (4 A, activated, 3.0 g)
  • anhydrous CH 2 Cl 2 150 mL
  • anhydrous pyridine 5.3 mL, 65.0 mmol
  • the above solution A is added slowly over 10 minutes.
  • Hexane 200 mL
  • the resulting mixture is stirred at room temperature for 10 minutes.
  • N-methyl methanesulfonamide (6.0 g, 55.0 mmol), molecular sieves (4 A, activated, 3.0 g) and anhydrous CH 2 Cl 2 (150 mL).
  • N-methyl methanesulfonamide 6.0 g, 55.0 mmol
  • molecular sieves (4 A, activated, 3.0 g)
  • anhydrous CH 2 Cl 2 150 mL
  • anhydrous pyridine 5.3 mL, 65.0 mmol
  • the above solution A is added slowly over 10 minutes.
  • Hexane 100 mL
  • the resulting mixture is stirred at room temperature for 10 minutes.
  • Example 13 synthesis of fully protected dinucleotide phosphorothioate with isolation of intermediate H-phosphonate
  • Example 13-1 A mixture of 1.86g (2.62 mmol, 1.15 eq.) of H- phosphonate 1 and 0.78g (2.28 mmol) of 3 '-protected deoxy-thymidine 2 was co-evaporated with anhydrous pyridine (3x 25mL). The oily residue was dissolved in 1OmL of anhydrous pyridine and cooled to ⁇ 0 0 C under argon atmosphere. A total of 0.56g (4.66 mmol, 2 eq.) of pivaloyl chloride was added dropwise via syringe, and the resulting mixture was allowed to warm up to ambient temperature.
  • Example 13-2 By analogy with the method A, an intermediate H- phosphonate 3 was obtained by reaction of H-phosphonate 1 (1.49g, 2.1 mmol, 1.08 eq.) with 3 '-protected deoxythymidine 2 (0.66g, 1.94 mmol) in the presence of 0.49g (4.06 mmol, 2 eq.) of pivaloyl chloride in 2OmL of anhydrous pyridine. After quenching of the reaction mixture with cold water/aq.NaHCO3/brine, the intermediate 3 was isolated by extraction with dichloromethane (3x3 OmL). The organic extract was washed with water (5OmL), aq.
  • the reaction mixture was stirred at O 0 C for 5 min and partitioned between methylene chloride (100 mL) and 1.25 N sodium acetate - acetic acid buffer (2 x 100 mL).
  • the buffer was made by mixing 190 mL of 1.25 N aqueous sodium acetate solution with 10 mL of 1.25 N aqueous acetic acid solution.
  • the organic layer was dried (Na 2 SO 4 ) and concentrated.
  • Phosphorous acid 29.8 g, 364.0 mmol was rendered anhydrous by evaporation with pyridine (182 mL).
  • DMTr-Gp(s)T-OH 33.0 g, 26.0 mmol was added and the mixture was again rendered anhydrous by evaporation with pyridine.
  • the mixture was diluted with anhydrous pyridine (130 mL) and treated with pivaloyl chloride (24.0 mL, 195.0 mmol) which was added over 30 min at 10 0 C. The mixture was stirred for 16 hours at room temperature, concentrated, and the residue was dissolved in 400 mL of methylene chloride.
  • the solution was washed sequentially with cold water (400 mL) and triethylammonium hydrogen carbonate (2.0 N, 200 mL x 3).
  • the organic layer was dried (anhydrous Na 2 SO 4 ) and concentrated.
  • the mixture was filtered and the solid was washed with a solvent mixture made from the solution A and CH 2 Cl 2 in the ratio of 5: 1 (180 mL).
  • Phosphorous acid (4.7 g, 57.3 mmol) was evaporated with pyridine (29 mL) and mixed with OMT ⁇ -Gp(s)Tp(s)Gp(s)A-OR (8.7 g, 3.58 mmol). The mixture was rendered anhydrous by was anhydrous by evaporation of added pyridine and diluted with anhydrous pyridine (29.0 mL). To the stirred mixture, pivaloyl chloride (3.75 mL, 30.4 mmol) was added over 5 min at 10 0 C. The mixture was stirred for 6 hours at room temperature and concentrated.
  • the mixture was filtered and the solid was washed with a solvent mixturwe made from the solution A and CH2C12 in the ration of 5: 1 (120 mL).
  • the solid was extracted with methylene chloride (100 mL x 4) and the extract concentrated.
  • the residue was dissolved in 70 mL of acetonitrile and treated with cold water (49 mL) added over 30 min.
  • Gp(s) Tp(s) Gp(s)Ap(s) Gp(s) Tp(s) Gp(s)Ap(s) Gp(s) Tp(s) Gp(s)A-Lev (6.1 g, 0.89 mmol) was rendered anhydrous by evaporation with pyridine. The residue was diluted with anhydrous pyridine (10 mL) and treated under N 2 at O 0 C with pivaloyl chloride (0.37 mL, 3.0 mmol) which was added slowly over 3 min. The cold bath was removed and the mixture was stirred at ambient temperature for 1 hour.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

An oligonucleotide which comprises at least one internucleotide linkage comprising a P-S-R bond and at least two nucleosides, wherein R corresponds to the formula (I) wherein A is a geminally substituted alkylene group, preferably CH2, X and Y are independently selected from S and O, and R0 is selected from the group consisting of optionally substituted carbon bonded organic residue, such as in particular optionally substituted alkyl or aryl, SRx, ORx and NRxRy wherein Rx and/or Ry are selected from H and organic residues and at least Rx is a substituent other than H. Another object of the invention is a sulfurizing agent useful for oligonucleotide manufacture and the manufacture thereof.

Description

Sulfurizing reagents and their use for oligonucleotides synthesis
The present application claims the benefit of U.S. application No. 61/140391, filed December 23, 2008, the whole content of which being herein incorporated by reference. Technical Field The present invention relates to phosphorothioate oligonucleotides, the preparation thereof using novel sulfurizing reagents, said sulfurizing reagents and the preparation thereof. Background Art
Oligonucleotides belong to a class of biopharmaceuticals with a great potential for therapies of various diseases including cancer, viral infections and inflammatory disease to name a few. An important approach to advancing oligonucleotides as therapeutics involve modifications of the oligomer backbone to provide, among other things, metabolic resistance, chemical stability and to improve in vivo transport to the site of action. Examples of modified backbone chemistries include: peptide nucleic acids (PNAs) (see Nielsen, Methods MoI. Biol, 208:3-26, 2002), locked nucleic acids (LNAs) (see Petersen & Wengel, Trends Biotechnol., 21(2):74-81, 2003), phosphorothioates (see Eckstein, Antisense Nucleic Acid Drug Dev., 10(2): 117-21, 2000), methylphosphonates (see Thiviyanathan et al., Biochemistry, 41(3):827-38, 2002), phosphoramidates (see Gryaznov,
Biochem. Biophys. Acta, 1489(1): 131-40, 1999; Pruzan et al., Nucleic Acids Res., 30(2):559-68, 2002), thiophosphoramidates (see Gryaznov et al., Nucleosides Nucleotides Nucleic Acids, 20(4-7):401-10, 2001; Herbert et al., Oncogene, 21(4):638-42, 2002). Formation of phosphorothioates belongs to the most useful modifications since the replacement of P=O with P=S moiety makes the oligonucleotides resistant to nucleo lytic degradation while retaining in most cases the biological properties of natural oligomers.
Phosphorothioates can be formed by oxidative sulfurization (Oligonucleotide synthesis, methods and applications, P. Herdewijn Methods in Molecular Biology, volume 288, Chapter 4, 51-63). There are basically two approaches to making phosphorothioates depend upon the nature of phosphorous esters used for this reaction and the expected products. One of them involves introduction of the unsubstituted sulfur atom to phosphorus by means of, for example, elemental sulfur, dibenzoyl tetrasulfide, 3-H-l,2- benzodithiol-3-one 1,1 -dioxide (also known as Beaucage reagent, (Iyer et al., J. Org. Chem. 55, 4693-4699 (1990)), tetraethylthiuram disulfide (TETD), dimethylthiuram disulfide (DTD) , phenylacetyl disulfide (PADS) and bis(O,O-diisopropoxy phosphinothioyl) disulfide (known as Stec's reagent. These reactions are mostly used in the automated synthesis of oligonucleotides on solid support by the phosphoramidite method and comprise the oxidative sulfurization of phosphorus triesters formed during the elongation reaction of oligomers
A second approach to making oligomeric phosphorothioates is used with the H-phosphonate method and involves a reaction between H- phosphonate diester and a sulfur transfer reagent in which the sulfur atom, bearing an aliphatic or aromatic substituent, is transferred to phosphorus. The auxiliary substituent at sulfur serves the role of a protecting group during the synthetic operation and usually is cleaved at the final stage of oligonucleotide preparation. This method is particularly suitable for the synthesis of oligonucleotides in solution.
In contrast to large selection of reagents available for introducing the unsubstitued sulfur atom to phosphorus esters, the spectrum of groups allowing for sulfurization of H-phosphonate esters with the protected sulfur is limited (e.g. Dreef, et al. Synlett, 481-483,1990, US 6,506,894). Practically, only the cyanoethylsulfϊde group has been used extensively in this reaction during the solution synthesis of oligonucleotides with chromatographic purification at each step. A critical problem in the solution synthesis of oligonucleotides concerns the necessity to obtain high substrate conversions with excellent specificity at each synthetic step giving high purity products in a form that facilitates simple purification, in particular avoiding chromatography. Given the lack of methods allowing for economical solution phase synthesis, the solution phase technology does not seem to be currently used for commercial scale oligonucleotide synthesis.
The invention now discloses novel sulfurizing reagents, a process for their manufacture and their use in the economical and convenient synthesis and purification of phosphorothioate oligonucleotides notably in solution. Disclosure of Invention
The present invention relates in particular to the invention described in the appended claims. The invention also relates to processes and reagents substantially described in the present specification, in particular in the examples.
The invention has a number of advantages over existing methods of P-S linkage formation, in particular in the synthesis of oligonucleotides carried out preferably via the H-phosphonate method. For example, the residue R transferred e.g. to an oligonucleotide with the novel reagent can facilitate crystallization or precipitation of oligonucleotides, allowing for simple purification of the products with minimum or no chromatography. It has been found out that the oligonucleotides having from two to at least sixteen nucleotide units made with this method do not necessarily have to be purified by chromatography until after the final deprotection of the required oligonucleotide. The intermediate oligomers can be obtained pure enough for optional deprotections at the 5'- and 3' - positions and further coupling of these crude deprotected materials to higher oligonucleotides, if desired. In another advantage, the disclosed method provides an access to a variety of sulfurizing reagents which can be used to modify the properties of formed oligonucleotides with respect to maximizing the efficiency of simple, chromatography- free purifications. Still another advantage of the method according to the invention is that a simple cleavage of for example the sulfur- protecting acyloxymethylene group RC(O)-OCH2 can be easily accomplished under mild conditions, for example, with primary or secondary or hindered amines e.g. n-propylamine or tert-butylamine. Upon the optional treatment with an amine, a spontaneous cleavage, including the sulfur-methylene bond occurs thus allowing for the clean formation of P=S bond. The cleavage products can be easily removed from the products by solvent or aqueous wash. The stability characteristics for example of the acyloxymethylene group e.g. under basic non-nucleophilic conditions allow for selective deprotection reactions along the synthesis pathways and hence greater flexibility of synthesis schemes, for example by preventing the cleavage of nucleobase protection groups.
An important factor in developing an economical process for the synthesis of oligonucleotides, especially in solution, is the purity of the transformation product at each step of oligonucleotide chain elongation. Even though the process according to the invention secures high yields and purity of the products, each elongation cycle comprises generally three steps and it is advantageous to remove even small amounts of impurities which would otherwise accumulate along the way. Because of large number of steps, the use of chromatography at each step may not be economically feasible in the practical large scale oligonucleotide synthesis. Therefore, we also disclose a chromatography- free methodology for the purification of oligonucleotides formed during the chain elongation process.
A first particular object of this invention is to provide oligonucleotides which comprise at least one internucleotide linkage comprising a P-S-R bond and at least two nucleosides, wherein R corresponds to the formula (I)
wherein A is a geminally substituted alkylene group, preferably CH2, X and Y are independently selected from S and O, and Ro is selected from the group consisting of optionally substituted carbon bonded organic residue, such as in particular optionally substituted alkyl or aryl, SRx, ORx and NRxRy wherein Rx and Ry are selected from H and organic residues and at least Rx is a substituent other than H.
It has been found that the oligonucleotides according to the invention are valuable synthesis intermediates for synthesis of P-sulfurized oligonucleotides which have advantageous properties as to their solubility characteristics thus allowing for efficient purification which can be effectively accomplished, for example, by a combination of precipitation and extraction techniques. The oligonucleotides according to the invention are also believed to be effective as pro-drug, capable to release a phosphorothioate oligonucleotide in vivo, by cleavage of the R-group in the human body or in the body of an animal.
The term "oligonucleotide", in the frame of the present invention, denotes in particular an oligomer of nucleoside monomeric units comprising sugar units connected to nucleobases, said nucleoside monomeric units being connected by internucleotide bonds. An "internucleotide bond" refers in particular to a chemical linkage between two nucleoside moieties, such as the phosphodiester linkage typically present in nucleic acids found in nature, or other linkages typically present in synthetic nucleic acids and nucleic acid analogues. Such internucleotide bond may for example include a phospho or phosphite group, and may include linkages where one or more oxygen atoms of the phospho or phosphite group are either modified with a substituent or replaced with another atom, e.g., a sulfur atom, or the nitrogen atom of a mono- or di-alkyl amino group. Typical internucleotide bonds are diesters of phosphoric acid or its derivatives, for example phosphates, thiophosphates, dithiophosphate, phosphoramidates, thio phosphoramidates.
The term "nucleoside" is understood to denote in particular a compound consisting of a nucleobase connected to a sugar. Sugars include, but are not limited to, furanose ring such as ribose, 2'-deoxyribose and non-furanose ring such as cyclohexenyl, anhydrohexitol, morpholino. The modifications, substitutions and positions indicated hereinafter of the sugar included in the nucleoside are discussed with reference to a furanose ring, but the same modifications and positions also apply to analogous positions of other sugar rings. The sugar may be additionally modified. As non limitative examples of the modifications of the sugar mention can be notably made of modifications at e.g. the 2'-or 3'-position, in particular 2'-position of a furanosyl sugar ring including for instance hydrogen; hydroxy; alkoxy such as methoxy, ethoxy, allyloxy, isopropoxy, butoxy, isobutoxy, methoxyethyl, alkoxy, phenoxy; azido; amino; alkylamino; fluoro; chloro and bromo; 2 '-4'- and 3 '-4 '-linked furanosyl sugar ring modifications, modifications in the furanosyl sugar ring including for instance substitutions for ring 4'-0 by S, CH2, NR, CHF or CF2. The term "nucleobase" is understood to denote in particular a nitrogen- containing heterocyclic moiety capable of pairing with a, in particular complementary, nucleobase or nucleobase analog. Typical nucleobases are the naturally occurring nucleobases including the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U), and modified nucleobases including other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8- substituted adenines and guanines, 5-halo particularly 5-bromo, 5- trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8- azaadenine, 7-deazaguanine and 7-deazaadenine, 3-deazaguanine and 3- deazaadenine, and fluorinated bases. Further modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine(lH-pyrimido[5,4- b][l,4]benzoxazin-2(3H)-one), phenothiazine cytidine (lH-pyrimido[5,4- b][l,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido[5,4-b][l,4]benzoxazin-2(3H)- one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrido[3',2':4,5]pyrrolo[2,3-d]pyrimidin-2-one). Other potentially suitable bases include universal bases, hydrophobic bases, promiscuous bases and size-expanded bases.
"Oligonucleotide" typically refers to a nucleoside subunit polymer having from about 2 to about 50 contiguous subunits. The nucleoside subunits can be joined by a variety of intersubunit linkages. Further, "oligonucleotides" includes modifications, known to one skilled in the art, to the sugar backbone (e.g., phosphoramidate, phosphorodithioate), the sugar (e.g., 2' substitutions such as 2'-F, 2'-0Me), the base, and the 3' and 5' termini. Typically, in this invention the oligonucleotide comprises from 2 to 30 nucleotides. In different embodiments of this invention, the oligonucleotide contains nucleosides selected from ribonucleosides, 2'-deoxyribonucleosides, 2 '-substituted ribonucleosides, 2'-4'-locked-ribonucleosides, 3 '-amino- ribonucleosides, 3'- amino-2'-deoxyribonucleosides.
In some oligonucleotides of the invention, R is selected from a methyleneacyloxy group, a methylene carbonate group and a methylene carbamate group.
When R is a methyleneacyloxy group, it corresponds preferably to formula -CH2-O-C(O)-Ro wherein R0 is a C1-C20, saturated, unsaturated, heterocyclic or aromatic, hydrocarbon residue. When Ro is a saturated hydrocarbon residue, it is preferably selected from linear, branched or cyclic alkyl residues. Ro can for example be selected from lower alkyl or cycloalkyl (C1-C7) residues. Particular saturated hydrocarbon residues are selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert. butyl, cyclopentyl and cyclohexyl. A methyl, ethyl or n-propyl group is preferred. An ethyl group is more particularly preferred. When Ro is an aromatic residue, it is suitably selected from aromatic systems having from 6 to 14 carbon atoms. Particular aromatic residues are selected from phenyl and naphthyl groups which can be substituted, for example, by aryl or heteroaryl, alkyl, cycloalkyl, heterocycle or heterosubstitutents such as halogens,amines,ethers, carboxylates, nitro, thiols, sulfonic and sulfones. A phenyl group is preferred. When Ro is a heterocyclic residue, it is often selected from heterocycles containing at least one annular N, O or S atom which are bonded to the carbonyl group through an annular carbon atom. Particular examples of such heterocyclic residues include pyridine and furan.
In a particular aspect, the oligonucleotide comprises at least two internucleotide linkages comprising a P-S-R bond and at least three nucleotides, wherein R is a methyleneacyloxy group as described herein.
When R is a methylene carbamate group, it preferably corresponds to formula -CH2-O-C(O)- NRxRy wherein Rx and Ry are independently selected from alkyl or (hetero)aryl. Preferably Rx and/or Ry are alkyl groups. In this case Rx and/or Ry can for example be selected from lower alkyl or cycloalkyl (C1-C7) residues. Particular alkyl groups are selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert butyl, cyclopentyl and cyclohexyl. A methyl, ethyl or n-propyl group is preferred. In a particular preferred aspect, Rx and Ry in the methylene carbamate group are both alkyl groups, in particular as described herein before. A N,N-dimethyl or N5N- diethyl group is more particularly preferred. In another aspect of this embodiment Rx and Ry form together a 3 to 8 membered ring optionally containing an additional annular heteroatom selected from O, N and S. Particular examples include a N-piperidyl or an N-pyrrolidyl group.
When R is a methylene carbonate group, it corresponds preferably to formula -CH2-O-C(O) ORx wherein Rx is selected from optionally substituted alkyl, cycloalkyl and (hetero)aryl groups. Preferably, Rx is an alkyl group. In this case Rx can for example be selected from lower alkyl or cycloalkyl (C1-C7) residues. Particular alkyl groups are selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert butyl, cyclopentyl and cyclohexyl. A methyl, ethyl or n-propyl group is preferred. An ethyl group is more particularly preferred. When Rx is an aryl group, it is suitably selected from aromatic systems having from 6 to 14 carbon atoms. Particular aromatic residues are selected from phenyl and naphthyl groups. A phenyl group is preferred. When Rx is a heterocyclic residue, it is often selected from heterocycles containing at least one annular N, O or S atom which are bonded to the oxycarbonyl group through an annular carbon atom. Particular examples of such heterocyclic residues include pyridine and furan.
It is understood that the definitions and preferences of substituents Rx, Ry and Ro, given herein before for the case when R is selected from methyleneacyloxy group, a methylene carbonate group and a methylene carbamate group equally apply to the corresponding thioanalogues wherein X and/or Y in formula (I) are sulfur. It is also understood that the mentioned substituents may be optionally substituted, for example by halogen or alkoxy substituents or they may be modified, for example by inclusion of catenary heteroatoms, in particular oxygen into an alkyl chain.
A second particular object of this invention relates to a sulfurizing agent of formula R"-S-R wherein R is as defined here before in the context of the oligonucleotide according to the invention and R" is a leaving group.
It has been found that the sulfurization agent according to the invention allows for particularly efficient sulfur transfer, in particular to form S- protected phosphorthioate internucleotide linkages in oligonucleotides. The sulfurizing agent according to the invention introduces a protected sulfur from which the protective group can be cleaved selectively and efficiently.
In the sulfurizing agent according to the invention, the leaving group R" is generally an electrophilic group. Often, R" is a group containing an electrophilic nitrogen atom bonded to the sulfur. The electrophilic nitrogen atom is suitably substituted with at least one electron- withdrawing group.
In a particular embodiment of the sulfurizing agent of the invention, the sulfurizing agent corresponds to formula (II)
RA R-S'%° wherein RA and RB are equal or different from each other and at least one of RA and RB is selected from substituted sulfonyl or an acyl group, said RA and RB optionally forming together a cyclic substituent.
When at least one, preferably one, of RA and RB is substituted sulfonyl, it is generally selected from alkyl and aryl sulfonyl groups. When, preferably, at least one of RA and RB is an alkyl sulfonyl group, the alkyl substituent therein is preferably selected from lower alkyl or cycloalkyl (C1-C7) residues. Particular alkyl groups are selected from methyl, ethyl, n-propyl, isopropyl, n- butyl, sec-butyl, tert-Butyl, cyclopentyl and cyclohexyl. A methyl, ethyl or n- propyl group is preferred. A methyl group is more particularly preferred. When, at least one of RA and RB is an aryl sulfonyl group, the aryl substituent therein is, for example, an, optionally substituted, phenyl group. When at least one, preferably both, of RA and RB is an acyl group, it is generally selected from alkyl and aryl acyl groups. When, preferably, at least one of RA and RB is an alkyl acyl group, the alkyl substituent therein is preferably selected from lower alkyl or cycloalkyl (C1-C7) residues. Particular alkyl groups are selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert butyl, cyclopentyl and cyclohexyl. A methyl, ethyl or n-propyl group is preferred. A methyl group is more particularly preferred. In a particularly preferred embodiment, RA and RB are acyl groups forming together a cyclic substituent, preferably a 4 to 7 membered ring
In a specific embodiment, the sulfurizing agent corresponds to formula (III)
O R4
O O wherein Ri, R3 and R4 are independently a C1-C20, optionally unsaturated or aromatic, hydrocarbon residue, preferably a linear or branched alkyl group or a cycloalkyl group.
In a further specific embodiment of the sulfurizing agent according to the invention R" is a dicarboxylamide. In a particular aspect of this embodiment the sulfurizing agent corresponds to formula (IV)
Figure imgf000010_0001
wherein Z is an group, chosen among the group of -CH2-CH2- ,
-CH=CH-, -CH2-O-CH2- ,
Figure imgf000010_0002
, preferably Z is a group. A third particular object of the invention relates to a process for the synthesis of the sulfurizing agent according to the invention which comprises (a) reacting a sulfuryl halide, preferably sulfuryl chloride with a thioacetal of formula R-S-C(O)-R2 wherein R is as described previously and R2 is an organic residue, preferably selected from a C1-C20 optionally unsaturated or aromatic hydrocarbon residue to produce an intermediate product of formula R-S-W, wherein W is halogen preferably Cl and, (b) reacting said intermediate product with an N-sulfonyl compound or an N-acyl compound. In more specific embodiment of this invention, the thioacetal is of formula Ri- C(O)-O-CH2-S-C(O)-R2 wherein Ri and R2 are independently a C1-C20 optionally unsaturated or aromatic hydrocarbon residue and said thioacetal is reacted with sulfuryl chloride to produce an intermediate product of formula Ri-C(O)-O-CH2-S-Cl, wherein Ri is independently a C1-C20, optionally unsaturated or aromatic, hydrocarbon residue. In another specific embodiment of this invention, in step (b) the intermediate is reacted with an N-sulfonyl compound of formula R3-S (O)2-NH-R4, wherein R3 and R4 are independently organic residues, preferably a C1-C20, optionally unsaturated or aromatic, hydrocarbon residue .
In the process according to the invention for the synthesis of a sulfurizing agent, the reaction of step (a) is generally carried out in an aprotic polar organic solvent such as for example a halogenated hydrocarbon solvent, in particular a chlorinated hydrocarbon solvent such as methylene chloride. In the process according to the invention for the synthesis of a sulfurizing agent, the reaction of step (a) is generally carried out at a temperature of from -8O0C to 300C.
In the process according to the invention for the synthesis of a sulfurizing agent, the reaction of step (b) is generally carried out in an aprotic polar organic solvent such as for example a halogenated hydrocarbon solvent, in particular a chlorinated hydrocarbon solvent such as methylene chloride.
In the process according to the invention for the synthesis of a sulfurizing agent, the reaction of step (b) is generally carried out at a temperature of from -200C to 500C, preferably from 00C to 300C. A fourth particular object of this invention concerns a method for manufacturing an oligonucleotide using the sulfurizing agent according to the invention.
Generally, the method according to the invention comprises at least (a) a coupling step wherein a phosphorus internucleotide linkage is formed between two reactants selected from nucleotides and oligonucleotides and (b) a sulfurization step wherein the sulfurizing agent according to the invention is used to sulfurize said phosphorus internucleotide linkage. Steps (a) and (b) can be repeated after 3' or 5' deprotection of the sulfurized oligonucleotide. Step (a) of said manufacturing method preferably comprises forming the H-phosphonate diester bond by coupling an H-phosphonate monoester salt with a protected nucleoside or oligonucleotide having a free hydroxy group. The coupling is preferably carried out in solution phase.
Step (a) is preferably carried out in an aprotic polar organic solvent for example a halogenated solvent or nitrogen containing solvents, more particularly N-heterocyclic solvents or chlorinated hydrocarbon, even more particularly acetonitrile and pyridine and preferably pyridine. The reaction to form an H-Phosphonate diester is preferably activated by a carboxylic acid halide, in particular pivaloyl chloride.
Step (a) is generally carried out at a temperature from -400C to 300C, preferably from 00C to 200C .
In step (a) the process according to the invention and in the particular embodiments thereof, the liquid reaction medium generally contains at least 20% by weight of H-phosphonate oligonucleotide relative to the total weight of the reaction medium. Preferably this content is at least 20% weight. The liquid reaction medium generally contains at most 50% by weight of H- phosphonate oligonucleotide relative to the total weight of the reaction medium.
The coupling product of step (a), in particular an H-Phosphonate, may be isolated and subsequently sulfurized in step (b). It may also, preferably, be used without isolation in step (b). Sulfurization of formed diester can be carried by in-situ addition of the sulfurizing reagent, suitably dissolved in an appropriate solvent, or after pre-purifying formed diester from the reaction mixture.
Step (b) is preferably carried out in an aprotic polar organic solvent such as for example a solvent comprising a halogenated hydrocarbon solvent, in particular a chlorinated hydrocarbon solvent such as methylene chloride. In a particular aspect, step (b) is carried out in a solvent mixture comprising a halogenated hydrocarbon solvent and nitrogen containing solvents, more particularly N-heterocyclic solvents, preferably pyridine. A pyridine/methylene chloride mixture is more particularly preferred, in particular when the coupling product of step (a) is sulfurized without isolation.
Step (b) is generally carried out at a temperature of from -400C to 300C, preferably from 00C to 200C. In step (b), the molar ratio of sulfurizing agent relative to the amount of internucleotide linkages to be sulfurized is generally at least 1, often from 1.5 to 4.0, preferably from 2.0 to 3.0.
In step (b) the intermediate H-phosphonate diester is preferably activated by by an activator, in particular a base. Suitable bases include alkylamines, in particular tertiary alkylamines, diisopropylethylamine is preferred.
In a fifth aspect, the invention, relates to a method for purifying an oligonucleotide in accordance with the invention having at least one P-S-R linkage as described herein before. In one embodiment of this aspect, the method comprises at least precipitating the second oligonucleotide. In more specific embodiments, this method further comprise extraction of the second oligonucleotide, in particular from solid material recovered from the precipitation step, with a solvent. Suitable solvents for extraction include a polar organic solvent
It has been found that the purification can be effectively accomplished by a combination of precipitation and extraction techniques of the protected oligonucleotide obtained according to the described method. The exact conditions of precipitation can be determined on account of given sequence and length of the oligonucleotide. The precipitation method generally comprises (a) dissolving the oligonucleotide in a polar organic solvent and (b) adding a non-polar organic solvent until the solution becomes turbid.
It has been found that the oligonucleotides according to the invention can generally be isolated and purified by precipitation. The solvent used to dissolve the oligonucleotide in step (a) is preferably selected from halogenated hydrocarbons such as methylene chloride and chloroform, nitrogen containing solvents such as acetonitrile and pyridine, and carbonyl-containing solvents such as acetone.
Generally, in step (a), a solvent volume is used ranging from about 0.5 (n+1) mL to about 2.0 (n+1) mL. Preferably, about 1.0 (n+1) niL, where n is the millimoles number of phosphorothioate triester linkages.
The solution of the second oligonucleotide is treated with a non-polar organic solvent preferably selected from hydrocarbons, for example alkane solvents such as hexane, ether solvent in particular MTBE and their mixtures, such as, preferably hexane/MTBE mixtures until the solution becomes turbid. In another particular embodiment the turbid solution is subsequently treated with a precipitation aid.
In this case the precipitation aid is generally selected from inert porous solids preferably selected from Celite, charcoal, wood cellulose and chromatography stationary phases such as silica or alumina.
In this case, the precipitation aid is generally used in an amount ranging from about 0.25 (n+1) g to about 1.5 (n+1) g, preferably, about 0.75 (n+1) g, where n is the millimoles number of phosphorothioate triester linkages.
Preferably, after adding the precipitation aid the mixture is treated with a second fraction of a non-polar organic solvent as described here before. The volume of said fraction generally ranges from about l(n+l) mL to about 4(n+l) mL, preferably, about 2.0 (n+1) mL, wherein n is the millimoles number of phosphorothioate triester linkages.
After precipitation, in particular when a precipitation aid is used, the obtained mixture is generally subjected to a solid/liquid separation operation such as, preferably, a filtration. The oligonucleotide is generally recovered from solid recovered from solid/liquid separation operation, in particular from precipitation aid by extraction with a polar organic solvent preferably selected from carbonyl-type solvents such as acetone, from nitrogen-containing solvents such as acetonitrile and from halogenated hydrocarbons such as methylene chloride and chloroform.
The oligonucleotide obtained from the above precipitation treatment can be further purified by partitioning between an organic solvent and water. This step usually separates polar impurities, which dissolve in aqueous layer, from the product. In this embodiment, the oligonucleotide is suitably dissolved in a organic solvent, in particular a polar organic solvent such as nitrogen- containing solvents in particular selected from acetonitrile, formamides such as DMF and N-hetero cycles such as pyridine, carbonyl-type solvents such as acetone, or THF or DMSO. The volume of organic solvent used is generally ranging from 2.0 (n+1) mL to 8.0 (n+1) mL, preferably, about 4.0 (n+1) mL, where n is the millimoles number of the phosphorothioate triester linkage. The solution is treated with an aqueous medium, in particular water. The volume of aqueous medium used is generally from about 0.5 volume equivalent of the organic solvent to about 1.5 volume equivalent of the organic solvent, usually about 0.7 volume equivalent of the organic solvent. After treatment with the aqueous medium, an oligonucleotide-containing layer is generally separated and can be further processed, if appropriate, to obtain purified oligonucleotide.
A sixth particular object of this invention concerns a method for producing a second oligonucleotide having at least one phosphothioate group, which comprises (a) providing a first oligonucleotide according to the invention and (b) cleaving at least one R group, from said first oligonucleotide to produce said second oligonucleotide having at least one thiophosphate linkage. In some specific embodiments of the invention the R group, is cleaved by reacting the first oligonucleotide in solution with a base chosen preferably from alkyl, cycloalkyl and aromatic amines, more preferably from primary, for example an alkyl primary amine wherein alkyl group bears identical or different substituents selected preferably from Cl to C8 linear or branched alkyl or secondary alkyl amines, most preferably from n-propyl and tert-butyl amine, preferably the base is a hindered primary amine.
In a particular embodiment, the cleavage according to the sixth aspect of the invention is carried out in the presence of a sterically hindered base and of an activator which is generally a N-heteroaromatic base. Preferably activator is 1,2,4-triazole or other triazole and tetrazole derivatives, and more preferably such activator is used with a sterically hindered base, in particular tert-butyl amine.
The deprotection of S-methylene-ester, -carbonate or -carbamate group can be accomplished for example in a treatment of protected nucleotide with a sterically hindered base such as e.g. t-butylamine. These bulky amines are particularly selective because they do not react with the nucleobases, particularly those protected at carbonyl oxygen. They allow in fact limiting or substantially avoiding possible side-reactions with the nucleobase moiety. In order to improve reactivity of sterically hindered amines with, for example, S- methylenepropanoate under standard conditions, it was found that an activator may suitably be added. Examples of activators which are suitable include N- heterocyclic bases such as e.g. diazole, triazole, and their derivatives. This embodiment allows particularly clean, fast and efficient deprotection reactions.
In some embodiments of this invention the deprotection method involves using a substituted aniline as base wherein the aryl group of the aniline contains linear or branched alkyl or aryl substituents at 2 and/or 6 positions such as e.g. 2,6-dimethylaniline and 2,6-diethylaniline.
The deprotection according to the sixth aspect is preferably carried out in an aprotic polar organic solvent for example a solvent comprising nitrogen containing solvents, more particularly N-heterocyclic solvents, preferably pyridine.
The deprotection according to the sixth aspect is generally carried out at a temperature from -100C to 500C, preferably from 00C to 300C.
In the sixth aspect of the invention and in the particular embodiments thereof, the liquid reaction medium generally contains at least 20% by weight of first oligonucleotide relative to the total weight of the reaction medium. Preferably this content is at least 50% weight.
In the sixth aspect of the invention, the amount of base used is generally ranging from 5n mmol to 15n mmol, preferably about 1On mmol, where n is the millimoles number of the phosphorothioate triester linkage.
When an activator is used in the sixth aspect of the invention, the amount of activator used is generally ranging from 0.5n mmol to 3n mmol, preferably, 1.5n mmol, where n is the millimoles number of the phosphorothioate triester linkage. The following examples are intended to illustrate the invention without, however, limiting its scope EXAMPLES
In these examples and throughout this specification the abbreviations employed are defined as follows: CH2Cl2 is dichloromethane, KI is potassium iodide, Na2S2O3 is sodium thiosulfate, DME is dimethoxy ethane, DIPEA is diisopropylethylamine, NaCl is sodium chloride, MTBE is methyl tert-butyl ether, EtOAc is ethylacetate, HCl is hydrochloride acid, Na2SO4 is sodium sulfate, N2 is dinitrogen, Br2 is bromine, SO2Cl2 is thionyl chloride, NaHCO3 is sodium bicarbonate, CDC13 is deuterated chloroform, THF is tetrahydrofurane, DMSO is dimethylsulfoxide, DMF is N,N-dimethylformamide.
Ap, Gp, Tp are the 2-deoxyribose nucleobases as previous described respectively connected to A, G and T nucleobases as previously described wherein A, G and T are protected as follows: Ap is the 2-deoxyribose nucleobase wherein A is N-(purin-6- yl)benzamide, Gp is the 2-deoxyribose nucleobase wherein G is N-(6-(2,5- dichlorophenoxy)-purin-2-yl)isobutyramide and Tp is the nucleobase wherein T is 5-methyl-4-phenoxypyrimidin-2-one.
Ap(S), Gp(S) and Tp(S) are the corresponding 4'0-P-thiomethyl propionates of respectively Ap, Gp and Tp as previously described. Ap(H), Gp(H) and Tp(H) are the corresponding 4'0-P-H phophonates of respectively Ap, Gp and Tp as previously described.
DMTr is the bis para-methoxy trityl protecting group, known to one skilled in the art, bonded to the 5-0' of the corresponding oligonucleotide as previously described, when linked to it. Lev is the pentanl,4-dione protecting group, known to one skilled in the art, bonded to the 3-0' of the corresponding oligonucleotide as previously described, when linked to it.
The convention of abbreviations used in the description of invention is further illustrated by the following schemes.
Figure imgf000017_0001
Figure imgf000018_0001
DMTr-Gp(S)T-OH Example 1: Synthesis of bis-chloromethyl disulfide
-HCI
,SCl, -CU ,Sx aq Kl > CU Cl "Cl
To a 1.0 L round bottom flask were added anhydrous CH2Cl2 (200 rnL) and dimethyl disulfide (27.1 mL, 300 mmol). The mixture was stirred and cooled to -78 C under a N2 atmosphere, and Cl2 gas was bubbled slowly through the stirred mixture. The addition of Cl2 gas was stopped after the mixture turned into a yellow-green slurry. The cold bath was removed and the mixture was warmed spontaneously to room temperature. A red solution was formed as the evolution of HCl was going out of the solution. The mixture was first bubbled with N2 for 15 min, and then rotary evaporated to remove volatile CH2Cl2. To the residue, fresh CH2Cl2 (300 mL) was added. The solution was stirred in an ice-water bath, an aqueous solution of KI (139.4 g, 840 mmol) in water (200 mL) was added slowly over 15 min. The cold bath was removed and the mixture was stirred at ambient temperature for 2 hours. The organic layer was separated and stirred in an ice-water bath; an aqueous saturated Na2S2O3 solution was added slowly until the color of I2 disappeared. The organic layer was separated, followed by washing with water (100 mL). The organic layer was dried over Na2SO4, followed by concentration to give product (42.2 g) as red oil. Yield: (87.3 %). This crude was used for next step without further purification. Example 2: Synthesis of bisfpropionyloxymethyDdisulfide
Figure imgf000019_0001
To a 1.0 L round bottom flask was added sodium iodide (1.50 g,
10.0 mmol), bis-chloromethyl disulfide (16.2 g, 100 mmol) and anhydrous DME (150 mL). After stirring at room temperature for 20 min, the mixture was cooled in an ice-water bath, and then DIPEA (42.0 mL, 240 mmol) was added, followed by propionic acid (16.4 mL, 220 mmol). The cold bath was removed and the mixture was stirred at room temperature for 18 hours. The bulk of the solvent was removed by rotary evaporation. Ethyl acetate (400 mL) was added to the residue, the mixture was then washed with water (150 mL x 2), followed by brine (80 mL). The organic layer was concentrated and the residue was purified by silica gel chromatography to give the desired product (9.62 g) as an orange oil. Yield: (40.4 %).
Example 3: Synthesis of N-methyl methanesulfonamide
Figure imgf000019_0002
Methanesulfonyl chloride (38.7 mL, 500 mmol) was added dropwise over 15 min to stirred aqueous methylamine (40% in water, 152 mL,
1.75 mol) cooled in an ice-water bath. The internal temperature was kept between 20 and 24 0C during addition. After addition, the cooling bath was removed and the mixture was stirred at room temperature overnight. NaCl (40 g) was added and the mixture was stirred at room temperature for 30 min. The mixture was extracted with CH2Cl2 (150 mL, 100 mL x 2). After drying over Na2SO4, the solvent was evaporated to give the desired product (48.7 g) as a colorless oil. Yield: 89.2%. Example 4: Synthesis of N-methyl-N-propionyloxymethylsulfanyl methanesulfonamide
Figure imgf000020_0001
To a 100 niL dry round bottom flask was added N-methyl methanesulfonamide (1.09 g, 10.0 mmol), pyridine (1.66 g, 21.0 mmol), bis(propionyloxymethyl)disulfide (1.2 g, 5.0 mmol) and anhydrous CH2Cl2 (8 mL). The mixture was stirred under N2 at room temperature and a solution ofBr2 (0.882 g, 5.52 mmol) in 4 mL Of CH2Cl2 was added dropwise over 30 min. The resulting mixture was stirred at room temperature for 2 hours. MTBE (15 mL) was added and the resulting mixture was filtered. The solid was washed with a mixture of CH2Cl2 (5 mL) and MTBE (5 mL). The filtrate was concentrated and purified by silica gel chromatography to give the desired product (1.62 g) as a colorless oil. Yield: 71.3%. Example 5: Synthesis of chloromethyl propionate
CH2O
O O ZnCI 12
Cl 5O 0C v O' "Cl
To a 500 mL dry round bottom flask was added paraformaldehyde
(90.1 g, 3000.0 mmol), anhydrous zinc chloride (8.18 g, 60.0 mmol). The bottle was placed in an ice-water bath, and propionyl chloride (260.6 mL, 3000.0 mmol) was added slowly over 1 hour. After addition, the mixture was stirred at 50 0C under N2 for 18 hours. The mixture was distilled to give the desired product 212.2 g as colorless oil. Yield: 58 %.
Example 6: Synthesis of propionic acid acetylsulfanylmethyl ester
Figure imgf000020_0002
To a 2000 mL dry three-necked round bottom flask, equipped with a mechanical stirrer, a dropping funnel and a N2 inlet, was added chloromethyl propionate (168.0 g, 1370.9 mmol), anhydrous CH2Cl2 (1000 mL), and diisopropylethylamine (194.9 g, 1508.0 mmol). To the stirred solution, cooled in an ice-water bath was added slowly thioacetic acid (98.0 mL, 1370.9 mmol) over 30 minutes. After addition, the mixture was stirred and warmed slowly to room temperature, and stirred at room temperature overnight. Most CH2Cl2 was rotary evaporated. To the mixture, a mixture of ethyl acetate
(500 mL) and MTBE (500 mL) was added. The mixture was filtered, and the solid was washed with a mixture of ethyl acetate (100 mL) and MTBE (100 mL). The filtrate was concentrated and the residue was distilled to give the desired product (169.8 g) as yellow oil. Yield: 76.4 %. Example 7: Synthesis of N-methyl-N-propionyloxymethylsulfanyl methanesulfonamide
Figure imgf000021_0001
To a 1000 mL dry round bottom flask was added propionic acid acetylsulfanylmethyl ester (70.0 g, 431.5 mmol), anhydrous CH2Cl2 (600 mL). The solution was stirred in an ice water bath under N2 and sulfuryl chloride (34.6 mL, 431.5 mmol) was added. After addition, the cold bath was removed and the mixture was stirred at room temperature for 1.5 hours. The mixture was rotary evaporated to remove all volatiles. The residue was dissolved in 80 mL of anhydrous CH2Cl2 to give solution A.
To another 1000 mL dry round bottom flask was added N-methyl methanesulfonamide (49.5 g, 453.1 mmol), molecular sieves (4 A, activated, 5.0 g) and anhydrous CH2Cl2 (200 mL). The solution was stirred in an ice water bath under N2, anhydrous pyridine (41.9 mL, 517.8 mmol) was added. After addition, the above solution A was added slowly over 15 minutes. The resulting mixture was then stirred at room temperature for 1.5 hours. Hexane (200 mL) was added slowly and the resulting mixture was stirred at room temperature for 10 minutes. The mixture was filtered, and the solid was washed with a mixture of ethyl acetate : hexane = 1:1 (80 mL). The filtrate was concentrated and the residue was purified on a column using 800 g of silica and sequential elution starting with hexane (21) followed by ethyl acetate/hexane (1 :9, 31), ethyl acetate/hexane (2:8, 41) and ethyl acetate/hexane (3:7, 21). The main impurity elutes at 20% of ethyl acetate and the product at 30% of ethyl acetate. Yield: 74.4%. Example 8: Synthesis N-methanesulfonamide succinimide
O O cn n, succinimide
Figure imgf000022_0001
Figure imgf000022_0002
A solution of 9.803g (60.43 mmol) of acetylsulfanylmethyl in 8OmL of anhydrous dichloromethane was placed in a 250 rnL 3 -neck round bottom flask equipped with a magnetic stirrer, thermocouple, nitrogen line and cooling ice bath. The flask's content was chilled to ~0 0C, and a total of 11.33g (83.94 mmol, 1.38 eq.) of sulfuryl dichloride was slowly added to the solution with the rate to maintain temperature between 0 and 5 0C. Cooling bath was removed, and reaction mixture was stirred at room temperature for additional 1,5 hour. The resulting yellow solution was concentrated on rotavap to yield 8.88g of crude acetylmethylsulfenyl chloride as stench viscous yellow oil. This material was immediately used in the next step for the sulfenylation of succinimide. A mixture of 6.12g (61.76 mmol, 1.02 eq.) of succinimide and 8.17g
(80.73 mmol, 1.33eq.) of triethylamine in 8OmL of anhydrous dichloromethane was placed in a 25OmL 3 -neck round bottom flask equipped with a magnetic stirrer, thermocouple, nitrogen line and cooling ice bath. This mixture was cooled to 0 0C, and a solution of crude acetylmethylsulfenyl chloride (8.88g) in 2OmL of anhydrous dichloromethane was slowly added to the pre-chilled suspension of succinimide and triethylamine with the rate to maintain temperature between 00C and 50C. After completion of addition, cooling bath was removed and resulting brown suspension was allowed to stir at room temperature for additional 2 hours. The reaction mixture was quenched with cold water (30OmL) and saturated NaHCOs (10OmL), and extracted with dichloromethane (3x80mL). Organic phases were combined, dried over Na2SO4 and concentrated on rotavap to yield 13g of dark viscous oil. This material was purify on silica gel column (12Og) using EtOAc-hexane mixture as eluent with 0 to 30% of ethylacetate to give 4.12g of sulfenamide N-methanesulfonamide succinimide as white solid, R^O.16 in 30% EtOAc- hexane. Yield : 32%. Example 9: synthesis of ethyl acetylsulfanylmethyl carbonate
Figure imgf000023_0001
To a 100 niL dry round bottom flask is added chloromethyl chloroformate (12.9 g, 100.0 mmol), anhydrous acetonitrile (300 mL). The solution is stirred in an ice-water bath, and a mixture of anhydrous ethanol (4.6 g, 100.0 mmol) and anhydrous pyridine (23.7 g, 300 mmol) is added slowly over 20 min. After addition, the mixture is stirred at room temperature for 1 hour. Sodium iodide (1.50 g, 10.0 mmol) is added into the reaction mixture. The mixture is stirred in an ice-water bath, and thioacetic acid (7.6 g, 100 mmol) is added over 5 min. After addition, the cold bath is removed and the mixture is stirred at room temperature overnight. Hexane (600 mL) is added into the reaction mixture and is filtered. The filtrate is concentrated and distilled to give the desired product. Example 10: Synthesis of N-methyl-N-ethoxycarbonyloxymethylsulfanyl methanesulfonamide 0
Figure imgf000023_0002
To a 500 mL dry round bottom flask is added ethyl acetylsulfanylmethyl carbonate (8.9 g, 50.0 mmol), anhydrous CH2Cl2 (200 mL ). The solution is stirred in an ice water bath under N2 and sulfuryl chloride (4.0 mL, 50.0 mmol) is added. After addition, the cold bath is removed and the mixture is stirred at room temperature for 1.5 hours. The mixture is rotary evaporated to remove all volatiles. The residue is dissolved in 50 mL of anhydrous CH2Cl2 to give solution A. To another 500 mL dry round bottom flask is added N-methyl methanesulfonamide (6.0 g, 55.0 mmol), molecular sieves (4 A, activated, 3.0 g) and anhydrous CH2Cl2 (150 mL). The mixture is stirred in an ice water bath under N2, anhydrous pyridine (5.3 mL, 65.0 mmol) is added. After addition, the above solution A is added slowly over 10 minutes. The resulting mixture is then stirred at room temperature for 1.5 hours. Hexane (200 mL) is added slowly and the resulting mixture is stirred at room temperature for 10 minutes. The mixture is filtered, and the solid is washed with a mixture of ethyl acetate : hexane = 1:1 (60 mL). The filtrate is concentrated and the residue is purified by a silica gel column to give the desired product. Example 11: synthesis of acetylsulfanylmethyl dimethylcarbamate
n Dimetylamine 9 9 1T?
M hydrochloride J[^ ^^ Thioacetic acid^ ^ JJ^ ^^ H
CI ^O^CI DIPEA " ^N O^CI Na| ^N O^S^
To a 100 niL dry round bottom flask is added chloromethyl chloroformate (12.9 g, 100.0 mmol), dimethylamine hydrochloride (8.15 g, 100 mmol) and anhydrous acetronitrile (300 mL). The mixture is stirred in an ice-water bath, and N, iV-diisopropylethyl amine (43.5 mL, 250 mmol) is added slowly over 30 min. After addition, the mixture is stirred at room temperature for 1 hour. Sodium iodide (1.50 g, 10.0 mmol) is added into the reaction mixture. The mixture is stirred in an ice-water bath, and thioacetic acid (7.6 g, 100 mmol) is added over 5 min. After addition, the cold bath is removed and the mixture is stirred at room temperature overnight. Hexane (300 mL) is added into the reaction mixture and is filtered. The filtrate is concentrated and distilled to give the desired product. Example 12: synthesis of N-methyl-N- dimethylcarbamoyloxymethylsulfanyl methanesulfonamide
Figure imgf000024_0001
To a 500 mL dry round bottom flask is added ethyl acetylsulfanylmethyl dimethylcarbamate (8.9 g, 50.0 mmol), anhydrous CH2Cl2 (200 mL ). The solution is stirred in an ice water bath under N2 and sulfuryl chloride (4.0 mL, 50.0 mmol) is added. After addition, the cold bath is removed and the mixture is stirred at room temperature for 1.5 hours. The mixture is rotary evaporated to remove all volatiles. The residue is dissolved in 50 mL of anhydrous CH2Cl2 to give solution A. To another 500 mL dry round bottom flask is added N-methyl methanesulfonamide (6.0 g, 55.0 mmol), molecular sieves (4 A, activated, 3.0 g) and anhydrous CH2Cl2 (150 mL). The mixture is stirred in an ice water bath under N2, anhydrous pyridine (5.3 mL, 65.0 mmol) is added. After addition, the above solution A is added slowly over 10 minutes. The resulting mixture is then stirred at room temperature for 1.5 hours. Hexane (100 mL) is added slowly and the resulting mixture is stirred at room temperature for 10 minutes. The mixture is filtered, and the solid is washed with a mixture of ethyl acetate : hexane = 1:1 (60 mL). The filtrate is concentrated and the residue is purified by a silica gel column to give the desired product. Example 13: synthesis of fully protected dinucleotide phosphorothioate with isolation of intermediate H-phosphonate
Figure imgf000025_0001
Example 13-1. A mixture of 1.86g (2.62 mmol, 1.15 eq.) of H- phosphonate 1 and 0.78g (2.28 mmol) of 3 '-protected deoxy-thymidine 2 was co-evaporated with anhydrous pyridine (3x 25mL). The oily residue was dissolved in 1OmL of anhydrous pyridine and cooled to ~0 0C under argon atmosphere. A total of 0.56g (4.66 mmol, 2 eq.) of pivaloyl chloride was added dropwise via syringe, and the resulting mixture was allowed to warm up to ambient temperature. The reaction stirred for an additional 15 min, and then was quenched with 5Og of ice and 10OmL of diluted saturated NaHCOs (8OmL water and 2OmL of sodium bicarbonate). The organic material was extracted with dichloromethane (2x80mL) and the extract was washed with a mixture of cold water (7OmL), saturated sodium bicarbonate (3OmL) and brine (1OmL). The organic layer was dried over anhydrous sodium sulfate and concentrated on rotavap to give 6.74g of crude 3 as clear oil. 31P (162 MHz, CDCl3, δ): 8.58 (s) and 7.06 (s).
A solution of crude H-phosphonate 3 (6.74g) in 2OmL of anhydrous pyridine was cooled to ~0 0C under argon atmosphere. A total of 1.2 Ig (5.43 mmol, 2.3eq.) of reagent 4 was added drop wise to the reaction, and after 5 min 0.502g (3.88 mmol, 1.7eq.) of diisopropylethyl amine was also added to the flask. The reaction was allowed to warm up to ambient temperature, and after an additional stirring for 1 hours it was quenched with diluted cold solution of sodium bicarbonate (10OmL). Organic products were extracted with dichloromethane (2x80mL), washed with water (10OmL) and dried over sodium sulfate. The organic phase was concentrated on rotavap to give 5.02g of crude 5 (-90% pure by HPLC) as yellow oil. 31P (162 MHz, CDCl3, δ): 26.77 (s) and 26.67 (s).
Example 13-2. By analogy with the method A, an intermediate H- phosphonate 3 was obtained by reaction of H-phosphonate 1 (1.49g, 2.1 mmol, 1.08 eq.) with 3 '-protected deoxythymidine 2 (0.66g, 1.94 mmol) in the presence of 0.49g (4.06 mmol, 2 eq.) of pivaloyl chloride in 2OmL of anhydrous pyridine. After quenching of the reaction mixture with cold water/aq.NaHCO3/brine, the intermediate 3 was isolated by extraction with dichloromethane (3x3 OmL). The organic extract was washed with water (5OmL), aq. NaHCO3 (2OmL) and brine (1OmL). After drying with Na2SO4 (for ~1 min), the organic phase was concentrated to ~ 1/4 of the original volume, cooled to 0 0C, and S-transfer reagent 4 (0.96g, 4.3 mmol, 2.2 eq.) was added to 3 following by addition of diisopropylethylamine (0.45g, 3.48 mmol, 1.8 eq.). After stirring at room temperature for an additional 1 hour, the reaction was quenched as described in Method A. Concentration of the organic phase on a rotavap yielded 3.55g of crude 5 as clear yellow oil with HPLC purity of 91%. Example 14: preparation of DMTr- Ap(s)T-Lev
A mixture of triethylammonium 6-iV-(bezoyl)-5'-0-(4, 4'- dimethoxytrityl) - 2 '-deoxyadenosine-3 'H-phosphonate (4.94 g, 6.0 mmol) and 3'-0-levulinylthymidine (1.70 g, 5.0 mmol) was rendered anhydrous by evaporation with pyridine, diluted with anhydrous pyridine (12.5 mL) and stirred under N2 at O0C. Subsequently, pivaloyl chloride (1.24 mL, 10.0 mmol) was added slowly over 2 min. The reaction mixture was stirred at O0C for 5 min and partitioned between methylene chloride (100 mL) and 1.25 N sodium acetate - acetic acid buffer (2 x 100 mL). The buffer was made by mixing 190 mL of 1.25 N aqueous sodium acetate solution with 10 mL of 1.25 N aqueous acetic acid solution. The organic layer was dried (Na2SO4) and concentrated. The residue was co-evaporated with 50 mL of toluene, dissolved in anhydrous methylene chloride (25 mL), and treated under N2 at O0C with a solution of N-propionyloxymethylthio-N-methyl methanesulfonamide (2.05 g, 9.0 mmol) in anhydrous methylene chloride (1.0 mL), followed by the addition of N, jV-diisopropylethylamine (0.87 mL, 5.0 mmol). After stirring at ambient temperature for 30 min, solution A (MTBE: Hexane = 1 : 2, 37.5 mL) was added over 10 min, followed by Celite (7.5 g). The mixture was stirred and the additional portion of A (37.5 mL) was added over 30 min. The stirring was continued for further 30 min, and the mixture was filtered. The solid was washed with a mixture of solvent made of the solution A and CH2Cl2 in the ratio of 5: 1 (60 mL). The solid then was extracted with methylene chloride (4 x 40 mL). The methylene chloride filtrate was concentrated. The residue was dissolved in acetonitrile (20 mL) and stirred in an ice-water bath, and cold water (14 mL) was added over 20 min. The bottom layer was partitioned between methylene chloride (100 mL) and aqueous (1 :1) brine solution (60 mL). The organic layer was dried (Na2SO4) and concentrated to give product (5.7 g) as white solid. Yield: 97%. 31P NMR (CDCl3, 121.5 MHz): δ = 26.7, 26.3. Example 15: preparation of DMTr-Gp(H):
To phosphorous acid (78.7 g, 960.0 mmol) which was made anhydrous by evaporation with pyridine (500 mL), 2'-deoxy-6-O-(2, 5-dichlorophenyl)- 5'-O-(4, 4'-dimethoxytrityl)-2-Λ/-isobutyrylguanosine (62.8 g, 80.0 mmol) was added and the mixture was again rendered anhydrous by evaporation with pyridine. The residue was treated with anhydrous pyridine (480 mL) and pivaloyl chloride (64.0 mL, 520.0 mmol) which was added over 30 min at 1O0C. The reaction mixture was stirred for 6 hours at room temperature and concentrated. The residue was dissolved in 800 mL of methylene chloride and washed sequentially with cold water (800 mL), triethylammonium hydrogen carbonate (2.0 N, 400 mL x 2). The organic layer was dried (anhydrous Na2SO4) and concentrated. The residue was dissolved in 80 mL of methylene chloride, and a solution A (MTBE : Hexane = 1 : 2, 360 mL) was added over 20 min under stirring followed by Celite (80 g). Subsequently, additional solution A (360 mL) was added slowly over 30 min. The mixture was filtered and the solid was washed with MTBE (300 mL). The solid was then extracted with methylene chloride (200 mL x 4). The methylene chloride filtrate was concentrated to give product (70.4 g) as white foam. Yield: 93%. 31P NMR (CDCl3, 121.5 MHz): δ = 2.71. Example 16: preparation of DMTr-Gp(s)T-OH
A mixture of triethylammonium 2 '-deoxy-6-O-(2,5-dichlorophenyl)-5'- 0-(4,4'-dimethoxytrityl)-2-JV-isobutyrylguanosine-3 'H-phosphonate (54.9 g, 58.0 mmol) and 3'-O-levulinyl-4-O-phenylthymidine (20.1 g, 48.3 mmol) was rendered anhydrous by evaporation with pyridine and diluted with anhydrous pyridine (121 mL). This solution was treated under N2 at O0C with pivaloyl chloride (11.8 mL, 96.6 mmol) over 5 min. After stirring for additional 5 min, a solution of N-propionyloxymethylthio-iV-methyl methanesulfonamide (22.0 g, 96.6 mmol) in anhydrous methylene chloride (20 rnL) was added, followed by N, JV-diisopropylethylamine (8.4 mL, 48.3 mmol). The reaction mixture was allowed to stir at ambient temperature for 30 min and was, diluted with 600 mL of methylene chloride. The organic layer was washed sequentially with cold water (600 mL), and saturated sodium bicarbonate (500 mL x 2), dried (anhydrous Na2SO4) and concentrated. The residue was dissolved in 97 mL of methylene chloride, and a solution A (MTBE : Hexane = 1 : 2, 194 mL) was added over 20 min under stirring followed by celite (73 g) and the additional portion of the solution A (194 mL) which was added over 30 min. After stirring for additional 30 min, the mixture was filtered. The solid was washed with MTBE : Hexane = 4 : 1 (200 mL and was extracted with methylene chloride (150 mL x 4). The methylene chloride filtrate was concentrated to give product (68.1 g) as yellow foam 31P NMR (CDCl3, 121.5 MHz): δ = 26.9, 26.2. This product was used for next step without further purification. To a stirred solution of the above product (64 g) in 117 mL of methylene chloride at O0C, a cold mixture of pyridine: acetic acid: hydrazine monohydrate = 37.5 mL: 25.0 mL: 2.5 mL (51.6 mmol) was added. After stirring at O0C for 1 hour, the reaction mixture was diluted with methylene chloride (200 mL) and was washed with cold water (500 mL). The aqueous layer was back extracted with methylene chloride (100 mL). The combined methylene chloride extracts were dried (anhydrous Na2SO4) and concentrated. The residue was dissolved in 235 mL of acetonitrile, stirred in an ice-water bath, and treated with cold water (188 mL) which was added gradually over 30 min. The bottom organic layer was separated, diluted with 200 mL of methylene chloride and dried (anhydrous Na2SO4). After concentration, the residue was dissolved in 94 mL of methylene chloride and treated sequentially under stirring by solution A (MTBE: Hexane = 1 : 2, 94 mL) added over 20 min, Celite (70 g) and again by the solution A (94 mL) added over 30 min. The mixture was filtered, the solid was washed with MTBE: Hexane = 4: 1 (300 mL) and extracted with methylene chloride (150 mL x 4). The methylene chloride filtrate was concentrated to give the product (52 g) as yellow foam. Yield: 87%. This product was used for next step directly. 31P NMR (CDCl3, 121.5 MHz): δ = 28.1, 25.3. Example 17: preparation of HO-Gp(s)A-Lev
A mixture of triethylammonium 2'-deoxy-6-0-(2,5-dichlorophenyl)-5'- O-(4,4'-dimethoxytrityl)-2-Λ/-isobutyrylguanosine-3'H-phosphonate (45.4 g, 48.0 mmol) and 2'-deoxy -3'-O-levulinyl-6-Λ/-benzoyladenosine (18.1 g, 40.0 mmol) was rendered anhydrous by evaporation with pyridine. The residue was diluted with anhydrous pyridine (100 mL), and the resulting solution was treated under N2 at O0C with pivaloyl chloride (9.9 mL, 80.0 mmol) over 10 min. The reaction mixture was stirred at O0C for additional 5 min and treated with a solution of Λ/-propionyloxymethylthio-iV- methyl methanesulfonamide (18.2 g, 80.0 mmol) in anhydrous methylene chloride (10 mL), followed by N, jV-diisopropylethylamine (7.0 mL, 40.0 mmol). After stirring at ambient temperature for 30 min, the reaction mixture was diluted with 600 mL of methylene chloride and washed sequentially with cold water (600 mL), and saturated sodium bicarbonate (300 mL x 2). The organic layer was dried (anhydrous Na2SO4) and concentrated. The residue was dissolved in 80 mL of methylene chloride, and treated sequentially with a solution A (MTBE: Hexane = 1 : 2, 160 mL) over 20 min, followed by Celite (60 g) and additional portion of solution A (160 mL) over 30 min. After stirring for 30 min, the mixture was filtered. The solid was washed with MTBE: Hexane = 4 : 1 (200 mL) and extracted with methylene chloride (150 mL x 4). The methylene chloride filtrate was concentrated. The residue was dissolved in 160 mL of acetonitrile, stirred in an ice-water bath, and treated with cold water (112 mL) over 30 min. The bottom organic layer was separated and partitioned between methylene chloride (320 mL) and water (320 mL). The organic layer was dried
(anhydrous Na2SO4) and concentrated to give product (64.1 g) as yellow foam. This product was used for next step without further purification. 31P NMR (CDCl3, 121.5 MHz): δ = 26.2, 26.0.
To a stirring solution of the above product (64.0 g) in 120 mL of methylene chloride at O0C, pyrrole (13.9 mL, 200.0 mmol) was added followed by dichloroacetic acid (16.5 mL, 200.0 mmol) addition over 20 min. After stirring at O0C for 1 hour, the reaction mixture was quenched with saturated sodium bicarbonate (200 mL). The aqueous layer was extracted with methylene chloride (60 mL x 2) and the combined methylene chloride extracts were dried (anhydrous Na2SO4) and concentrated. The residue was dissolved in 80 mL of methylene chloride, and treated sequentially with a solution A (MTBE: Hexane = 1 : 1, 100 niL) over 15 min, Celite (60 g) and an additional portion of solution A (100 mL) over 30 min. The mixture was filtered, the solid was washed with MTBE (150 mL x 2) and extracted with methylene chloride (200 mL x 4). The methylene chloride filtrate was concentrated, dissolved in 160 mL of acetonitrile, stirred in an ice-water bath, and treated with cold water (144 mL) over 20 min. The bottom organic layer was separated and partitioned between methylene chloride (320 mL) and aqueous (1:1) brine solution (320 mL). The organic layer was dried (anhydrous Na2SO4) and concentrated to give product (40.5 g) as off-white solid. Yield: 92%. 31P NMR (CDCl3, 121.5 MHz): δ = 26.4, 26.2. Example 18: preparation of DMTr- Gp(s)Tp(H)
Phosphorous acid (29.8 g, 364.0 mmol) was rendered anhydrous by evaporation with pyridine (182 mL). To the residue, DMTr-Gp(s)T-OH (33.0 g, 26.0 mmol) was added and the mixture was again rendered anhydrous by evaporation with pyridine. The mixture was diluted with anhydrous pyridine (130 mL) and treated with pivaloyl chloride (24.0 mL, 195.0 mmol) which was added over 30 min at 10 0C. The mixture was stirred for 16 hours at room temperature, concentrated, and the residue was dissolved in 400 mL of methylene chloride. The solution was washed sequentially with cold water (400 mL) and triethylammonium hydrogen carbonate (2.0 N, 200 mL x 3). The organic layer was dried (anhydrous Na2SO4) and concentrated. After co- evaporating with 150 mL of toluene, the residue was dissolved in 52 mL of methylene chloride, and treated sequentially with a solution A (MTBE: Hexane = 1 : 1, 78 mL) over 20 min, Celite (39 g) and an additional portion of the solution A (78 mL) over 30 min. The mixture was filtered and the solid was washed with a solvent mixture made from the solution A and CH2Cl2 in the ratio of 5: 1 (180 mL). The solid was extracted with methylene chloride (150 mL x 4), the filtrate was concentrated to give product (33.1 g) as off- white foam. Yield: 89%. 31P NMR (CDCl3, 121.5 MHz): δ = 26.9, 25.4, 3.0, 2.9.
Example 19: preparation of DMTr-Gp(s)Tp(s)Gp(s)A-OH
A mixture of triethylammonium salt of DMTr- Gp(s)Tp(H) (28.6 g, 20.0 mmol) and HO-Gp(s)A-Ley (16.9 g, 15.4 mmol) was rendered anhydrous by evaporation with pyridine. The residue was diluted with anhydrous pyridine (62.0 mL) and treated under N2 at O0C with pivaloyl chloride
(4.8 mL, 38.5 mmol) over 5 min. After stirring at O0C for additional 10 min, a solution of N-propionyloxymethylthio-iV-methyl methanesulfonamide (7.0 g, 30.8 mmol) in anhydrous methylene chloride (10 rnL) was added, followed by N, jV-diisopropylethylamine (2.7 mL, 15.4 mmol). After stirring at ambient temperature for 1 hour, the reaction mixture was diluted with 450 mL of methylene chloride and was washed sequentially with cold water (450 mL) and saturated sodium bicarbonate (300 mL x 2). The organic layer was dried (anhydrous Na2SO4) and concentrated. After co-evaporation with 100 mL of toluene, the residue was dissolved in 62 mL of methylene chloride, and treated sequentially with a solution A (MTBE: Hexane = 1 : 1, 124 mL) over 20 min, followed by Celite (46.2 g) and an additional portion of the solution A (124 mL) over 30 min. After stirring for 30 min, the mixture was filtered, the solid was washed with solution A: CH2Cl2 = 6: 1 (140 mL). The solid then was washed with methylene chloride (150 mL x 4). The methylene chloride filtrate was concentrated. The residue was dissolved in 123 mL of acetonitrile and treated with cold water (86 mL) over 20 min while stirring in an ice-bath. The bottom organic layer was separated and partitioned between methylene chloride (300 mL) and aqueous (1 :1) brine solution (200 mL). The organic layer was dried (anhydrous Na2SO4) and concentrated to give product DMTr- Gp(s)Tp(s)Gp(s)A-Lev (43.4 g) as yellow foam. This product was used for next step without further purification. 31P NMR (CDCl3, 121.5 MHz): δ = 27.9-25.8 (m).
To a stirring solution of DMTr- Gp (s) Tp (s) Gp (S)A-LGV (38.0 g) in 38.0 mL of methylene chloride at O0C, a cold mixture of pyridine : acetic acid : hydrazine monohydrate = 14.3 mL : 9.5 mL : 0.95 mL (19.5 mmol) was added. After stirring at O0C for 40 min, the reaction mixture was diluted with methylene chloride (450 mL) and washed with cold water (300 mL x 2) and brine (150 mL). The methylene chloride layer was dried (Na2SO4) and concentrated. After co-evaporated with 100 mL of toluene, the residue was dissolved in 60 mL of methylene chloride, and solution A (MTBE: Hexane = 1 : 1, 90 mL) was added over 20 min under stirring followed by celite (45 g). The mixture was stirred and more solution A (90 mL) was added over 30 min. The mixture was filtered and the solid was washed with a solvent mixture made from the solution A and CH2Cl2 in the ratio of 5: 1 (150 mL). The solid was extracted with methylene chloride (150 mL x 4), the extract was concentrated and the residue was purified with a short silica column using a gradient of acetonitrile 0-80% in ethyl acetate. The product fractions were concentrated to give the product (26.9 g) as yellow foam. Yield: 82%. 31P NMR (CDCl3, 121.5 MHz): δ = 27.6-26.0 (m). Example 20: preparation of nO-Gp(s)TD(s)Gp(s)A-hty
To a stirred solution of OMTτ-Gp(s)Tp(s)Gp(s)A-LQv (7.2 g, 2.84 mmol) in 14 mL of methylene chloride at O0C, pyrrole (2.0 mL,
28.4 mmol) was added followed by dichloroacetic acid (2.34 mL, 28.4 mmol) over 3 min. After stirring at O0C for 30 min, the reaction mixture was diluted withl4 mL of methylene chloride, followed by slow addition of saturated sodium bicarbonate (50 mL). The aqueous layer was extracted with methylene chloride (40 mL) and combined methylene chloride extracts were dried
(anhydrous Na2SO4) and concentrated. The residue was dissolved in 30 mL of methylene chloride, and treated sequentially with a solution A (MTBE: Hexane = 2: 1, 45.0 mL), Celite (9.0 g), and the solution A (45.0 mL) again over 30 min. The mixture was filtered, the solid was washed with MTBE (40 mL x 2) and extracted with methylene chloride (50 mL x 4). The methylene chloride extract was concentrated, the residue was dissolved in
28.4 mL of acetonitrile and treated while stirring in an ice-bath with cold water (28.4 mL) over 20 min. The organic layer was diluted with methylene chloride (80 mL) dried (anhydrous Na2SO4) and concentrated to give product (5.7 g) as off-white solid. Yield: 95%. 31P NMR (CDCl3, 121.5 MHz): δ =
27.4-26.2 (m). Example 21: preparation of DMTr-Gp(s)Tp(s)Gp(s)Ap(H)
Phosphorous acid (4.7 g, 57.3 mmol) was evaporated with pyridine (29 mL) and mixed with OMTτ-Gp(s)Tp(s)Gp(s)A-OR (8.7 g, 3.58 mmol). The mixture was rendered anhydrous by was anhydrous by evaporation of added pyridine and diluted with anhydrous pyridine (29.0 mL). To the stirred mixture, pivaloyl chloride (3.75 mL, 30.4 mmol) was added over 5 min at 10 0C. The mixture was stirred for 6 hours at room temperature and concentrated. The residue was dissolved in 200 mL of methylene chloride and washed sequentially with cold water (100 mL), and triethylammonium hydrogen carbonate (2.0 N, 100 mL x 3). The organic layer was dried (anhydrous Na2SO4) and concentrated to give the product (9.15 g) as off- white foam. Yield: 98%. 31P NMR (CDCl3, 121.5 MHz): δ = 27.5-25.8 (m), 2.9, 2.8. Example 22: preparation of HO- Gp(s)Tp(s)Gp(s)Ap(s)Gp(s)Tp(s)Gp(s)A-Lev
A mixture of triethylammonium salt of DMTr-Gp(s)Tp(s) Gp(s) Ap(H) (10.1 g, 3.9 mmol) and UO-Gp(s)Tp(s)Gp(s)A-LQv (6.7 g, 3.0 mmol) was rendered anhydrous by evaporation with pyridine and diluted with anhydrous pyridine (15.0 mL).. Pivaloyl chloride (1.1 mL, 9.0 mmol) was added slowly over 2 min to this mixture with stirring at O0C. The mixture was stirred at ambient temperature for 30 min, cooled again at O0C, and a solution of N- propionyloxymethylthio -//-methyl methanesulfonamide (1.70 g, 7.5 mmol) in anhydrous methylene chloride (2.0 mL) was added, followed by N, N- diisopropylethylamine (0.78 mL, 4.5 mmol). The reaction mixture was stirred at ambient temperature for 1 hour, and diluted with 300 mL of methylene chloride. The organic layer was washed sequentially with cold water (300 mL) and saturated sodium bicarbonate (200 mL), dried (anhydrous Na2SO4) and concentrated. The residue was dissolved in methylene chloride (24 mL), and treated sequentially with a solution A (MTBE: Hexane = 1 : 1, 48 mL) over 10 min, Celite (18 g), and an additional portion of the solution A (48 mL) over 30 min. After stirring for 30 min, the mixture was filtered, the solid was washed with MTBE: Hexane = 2: 1 (60 mL) and extracted with methylene chloride (50 mL x 4). The methylene chloride extract was concentrated; the residue was dissolved in acetonitrile (48 mL) and treated with cold water (34 mL) over 20 min while stirring in an ice-water bath. The bottom layer was separated and partitioned between methylene chloride (150 mL) and aqueous (1 :1) brine solution (160 mL). The organic layer was dried (anhydrous Na2SO4) and concentrated to give product (11.7 g) as a grey solid 31P NMR (CDCl3, 121.5 MHz): δ = 27.7-25.8 (m). This product was used in next step directly without further purification
To a stirring solution of above product (11.2 g) in 18 mL of methylene chloride at O0C, pyrrole (2.85 mL, 41.1 mmol) was added followed by dichloroacetic acid (3.2 mL, 38.4 mmol) over 5 min. After stirring at O0C for 40 min, the reaction mixture was quenched by slow addition of saturated sodium bicarbonate (40 mL). The mixture was diluted with 20 mL of methylene chloride, the aqueous layer was separated and extracted with methylene chloride (40 mL) and the combined methylene chloride extract were dried (anhydrous Na2SO4) and concentrated. The residue was dissolved in 28 mL of methylene chloride, and treated sequentially with a solution A (MTBE: Hexane = 1 : 1, 28 niL) over 10 min, Celite (16.8 g), and additional portion of the solution A (28 mL) over 20 min. The mixture was filtered; the solid was washed with solution A (40 mL) and MTBE (40 mL) and extracted with methylene chloride (4x50 mL). The methylene chloride extract was concentrated and purified with a short silica gel column. The column was eluted with methylene chloride. After concentration, product (8.7 g) was obtained as grey solid. Yield: 66%. 31P NMR (CDCl3, 121.5 MHz): δ = 27.8- 26.3 (m). Example 23: preparation of HO- Gp(s)Tp(s)Gp(s)Ap(s)Gp(s)Tp(s)Gp(s)Ap(s)Gp(s)Tp(s)Gp(s)A-Lev (SEQ. ID NO : 1)
A mixture of triethylammonium salt of DMΥr-Gp(s) Tp (s) Gp (s) Ap(H) (6.85 g, 2.64 mmol) and HO-Gp(s)Tp(s)Gp(s)Ap(s)Gp(s)Tp(s)Gp(s)A-LQγ (8.2 g, 1.81 mmol) was rendered anhydrous by evaporation with pyridine. To the residue, anhydrous pyridine (14 mL) was added, the resulting solution was stirred under N2 at O0C and treated with pivaloyl chloride (0.8 mL, 6.48 mmol) which was added over 3 min. The cold bath was removed and the mixture was stirred at ambient temperature for 30 min. The mixture was cooled to O0C, and a solution of Λ/-propionyloxymethylthio-iV-methyl methanesulfonamide (1.23 g, 5.40 mmol) in anhydrous methylene chloride (2.0 mL) was added, followed by N, iV-diisopropylethylamine (0.56 mL, 3.24 mmol). After stirring at ambient temperature for 1 hour, the reaction mixture was diluted with 250 mL of methylene chloride and was washed with cold semi-saturated sodium bicarbonate (250 mL). The organic layer was dried (anhydrous Na2SO4) and concentrated. The residue was co-evaporated with 50 mL of toluene, dissolved in 43 mL of methylene chloride, and treated sequentially with a solution A (MTBE: Hexane = 1 : 1, 43 mL) over 20 min, Celite (19.4 g) and an additional portion of the solution A (43 mL) over 30 min. After stirring for 30 min, the mixture was filtered, the solid was washed with a mixture made of the solution A and CH2Cl2 in the ratio of 4: 1 (100 mL x 2). The solid was extracted with methylene chloride (100 mL x 4), and the extract was concentrated. The residue was dissolved in 65 mL of acetonitrile and treated with cold water (46 mL) added over 20 min. The bottom organic layer was separated and partitioned between methylene chloride (200 mL) and aqueous (1 :1) brine solution (200 mL). The organic layer was dried (anhydrous Na2SO4) and concentrated to give product (12.8 g) as yellow foam. 31P NMR (CDCl3, 121.5 MHz): δ = 30.0-24.8 (m).
To a stirred solution of the above product (12.8 g) in 20 mL of methylene chloride at O0C, pyrrole (2.64 mL, 38.0 mmol) was added followed by dichloroacetic acid (3.0 mL, 36.0 mmol). After stirring further at O0C for 30 min, the reaction mixture was diluted with 200 mL of methylene chloride, followed by a slow addition of saturated sodium bicarbonate (100 mL). The organic layer was separated, dried (Na2SO4) and concentrated. The residue was dissolved in 40 mL of methylene chloride, and treated sequentially with a solution A (MTBE: Hexane = 1 : 1, 40 mL) added over 10 min, Celite (20 g) and additional portion of the solution A (80 mL) added over 20 min. The mixture was filtered and the solid was washed with a solvent mixturwe made from the solution A and CH2C12 in the ration of 5: 1 (120 mL). The solid was extracted with methylene chloride (100 mL x 4) and the extract concentrated. The residue was dissolved in 70 mL of acetonitrile and treated with cold water (49 mL) added over 30 min. The bottom organic layer was separated and partitioned between methylene chloride (150 mL) and aqueous (1 :1) brine solution (150 mL). The organic layer was dried (Na2SO4) and concentrated to give product (9.2 g) as off-white solid. Yield: 75%. This product was used for next step directly. 31P NMR (CDCl3, 121.5 MHz): δ = 27.7-26.4 (m). Example 24: preparation of HO-
GP(S)TP(S)GP(S)AP(S)GP(S)TP(S)GP(S)AP(S)GP(S)TP(S)GP(S)AP(S)GP(S) Tp(s)Gp(s)A-Lev: (SEQ. ID NO : 2)
A mixture of triethylammonium salt of OMTr- Gp (s) Tp (s) Gp (s) Ap(H) (3.64 g, 1.4 mmol) and HO-
Gp(s) Tp(s) Gp(s)Ap(s) Gp(s) Tp(s) Gp(s)Ap(s) Gp(s) Tp(s) Gp(s)A-Lev (6.1 g, 0.89 mmol) was rendered anhydrous by evaporation with pyridine. The residue was diluted with anhydrous pyridine (10 mL) and treated under N2 at O0C with pivaloyl chloride (0.37 mL, 3.0 mmol) which was added slowly over 3 min. The cold bath was removed and the mixture was stirred at ambient temperature for 1 hour. The mixture was cooled to O0C, and a solution of N- propionyloxymethylthio-N-methyl methanesulfonamide (568.3 mg, 2.5 mmol) in anhydrous methylene chloride (1.0 mL) was added, followed by N N-diisopropylethylamine (0.26 mL, 1.5 mmol). After stirring at ambient temperature for 1 hour, the reaction mixture was diluted with 120 mL of methylene chloride and washed sequentially with cold water (120 mL) and semi-saturated sodium bicarbonate (120 rnL). The organic layer was dried (anhydrous Na2SO4) and concentrated. The residue was dissolved in 32 rnL of methylene chloride, and treated sequentially with solution A (MTBE: Hexane = 1 : 1, 32 mL) added over 20 min, Celite (16.0 g), and an additional portion of the solution A (64 mL) added over 30 min. After stirring for 30 min, the mixture was filtered, the solid was washed with a solvent mixture made of the solution A and CH2Cl2 in the ratio 5: 1 (60 mL). The solid was extracted with methylene chloride (80 mL x 4) and the extract was concentrated. The residue was dissolved in 40 mL of acetonitrile and treated with cold water (28 mL) added over 20 min with stirring. The bottom organic layer was separated and partitioned between methylene chloride (150 mL) and aqueous (1 :1) brine solution (150 mL). The organic layer was dried (Na2SO4) and concentrated to give product (6.92 g) as yellow solid. 31P NMR (CDCl3, 121.5 MHz): δ = 27.6-26.3 (m). This product was used for next step without additional purification.
To a stirring solution of above product (6.92 g) in 10 mL of methylene chloride at O0C, pyrrole (1.74 mL, 25.0 mmol) was added followed by dichloroacetic acid (2.0 mL, 24.0 mmol) over 2 min. After stirring further at O0C for 30 min, the reaction mixture was diluted with 100 mL of methylene chloride, followed by addition of saturated sodium bicarbonate (50 mL) slowly. The organic layer was separated and the aqueous layer was extracted with 50 mL of methylene chloride. The combined CH2Cl2 extracts were dried (anhydrous Na2SO4) and concentrated. The residue was dissolved in 32 mL of methylene chloride, and treated sequentially with solution A (MTBE: Hexane = 1 : 1, 32 mL) added over 10 min, Celite (16 g) and an additional portion of the solution A (64 mL) added over 30 min. The mixture was filtered, the solid was washed with a solvent mixture made of the solution A and CH2Cl2 in the ratio of 5: 1 (90 mL). The solid was extracted with methylene chloride (80 mL x 4) and the extract was concentrated. The residue was dissolved in 40 mL of acetonitrile and treated with cold water (28 mL) which was added over 10 min while the mixture was stirred in an ice-bath. The bottom organic layer was separated and partitioned between methylene chloride (100 mL) and aqueous (1 :1) brine solution (100 mL). The organic layer was dried (anhydrous Na2SO4) and concentrated to give product (5.8 g) as yellow solid. Yield: 71%. 31P NMR (CDCl3, 121.5 MHz): δ = 27.7-26.3 (m). Example 25: Complete deprotection of 5'-OH fully-protected oligonucleotide phosphorothioate HO-Gp(s) Tp(s)Gp(s)A-Lev
Fully-protected tetramer HO-Gp(s)Tp(s)Gp(s)A-Leγ (1.38 g, 0.62 mmol) was rendered anhydrous by evaporation of added pyridine. To the residue, 1, 2, 4-triazole (192.7 mg, 2.79 mmol), 4A molecular sieve (1.5 g) and anhydrous pyridine (6.0 mL) were added. This mixture was stirred and cooled to 0 0C under N2, and te/t-butylamine (1.95 mL, 18.6 mmol) was added. The resulting mixture then was stirred at room temperature for 4 hours. The mixture was filtered and the molecular sieve was washed with pyridine (5 mL x 2). The combined filtrate was concentrated to dryness. To the residue, syn-2-pyridinealdoxime (909 mg, 7.44 mmol) was added, followed by anhydrous acetonitrile (10 mL). The mixture was stirred and cooled to 0 0C, and 1, 8-diazabicyclo[5.4.0]undec-7-ene (1.67 mL, 11.2 mmol) was added. After stirring at room temperature for 15 hours, MTBE (50 mL) was added slowly over 10 min. After stirring further for 20 min, the top clear solution was decanted, and the residue was rinsed with ethyl acetate (20 mL). The residue was evaporated to remove the residual solvents and was dissolved in a mixture of 28% aqueous ammonia (10.0 mL) and 2-mercaptoethanol (0.5 mL). The resulting mixture was heated at 55 0C for 15 hours. After cooling down the mixture was added dropwise to a stirring mixture of isopropanol: THF = 1 : 3 (80 mL) over 10 min. After stirring further for 20 min, the top clear solution was decanted, and the residue was rinsed with THF (20 mL). The residue was purified with a reversal Cl 8 chromatography. The product obtained was applied to a column (8 cm x 3 cm diameter) of Amberlite® IR- 120 (plus) ion-exchange resin (sodium form). The column was eluted with water, and the desired fractions were combined and lyophilized to give the sodium form of the fully-deprotected oligonucleotide phosphorothioate of product 684 mg as white solid. Yield: 83%. 31P NMR (D2O, 121.5 MHz): δ = 55.4-54.6 (m). Example 26: Synthesis of fully protected dinucleotide phosphorothioate as shown in scheme below
Figure imgf000038_0001
A solution of triethylammonium 5'-O-(4,4'-dimethoxytrityl)-thymidine- 3'- H-phosphonate (425.9 mg, 0.6 mmol), 3'-O-levulinyl thymidine (170.2 mg, 0.5 mmol) and dry pyridine (10.0 mL) was rotary evaporated to dryness. The residue was redissolved in 10 mL of pyridine and rotary evaporated again to dryness. To the residue, molecular sieves (300 mg, activated, 3A) and anhydrous pyridine (5.0 mL) were added. The mixture was stirred at room temperature under N2, pivaloyl chloride (0.22 mL, 1.75 mmol) was added. After stirring at room temperature for 5 min, a solution of N-methyl-N- propionyloxymethylsulfanyl methanesulfonamide (284.1 mg, 1.25 mmol) in CH2C12 (1.0 mL) was added, followed by DIPEA (0.17 mL, 2.0 mmol). The resulting mixture was stirred at room temperature for 30 min. Ethyl acetate (30 mL) was added. The mixture was filtered and the filtrate was washed with water (15 mL), semi-saturated aqueous sodium bicarbonate (15 mL x T) and brine (15 mL). The organic layer was dried and evaporated to give 1.2 Ig of pale yellow oil. This crude was purified by silica gel chromatography (EtO Ac/ Acetone) to give product (389 mg) as colorless foam. Yield: 74.4%.

Claims

C L A I M S
1. An oligonucleotide which comprises at least one internucleotide linkages comprising a P-S-R bond and at least two nucleosides, wherein R corresponds to the formula (I)
Figure imgf000039_0001
wherein A is a geminally substituted alkylene group, preferably CH2, X and Y are independently selected from S and O, and Ro is selected from the group consisting of optionally substituted carbon bonded organic residue, such as in particular optionally substituted alkyl or aryl, SRx, ORx and NRxRy wherein Rx and/or Ry are selected from H and organic residues and at least Rx is a substituent other than H.
2. The oligonucleotide according to claim 1 wherein R is selected from a methyleneacyloxy group, a methylene carbonate group and a methylene carbamate group.
3. The oligonucleotide according to any of claim 1 or 2, wherein R corresponds to formula -CH2-O-C(O)-Ro wherein Ro is a C1-C20, saturated, unsaturated, heterocyclic or aromatic, hydrocarbon residue.
4. The oligonucleotide according to any of claims 1 or 2, wherein R corresponds to a methylene carbamate group of formula -CH2-O-C(O)- NRxRy wherein Rx and Ry are independently selected from alkyl or (hetero)aryl preferably Rx and Ry are alkyl or Rx and Ry form together a 3 to 8 membered ring optionally containing an additional annular heteroatom selected from O,N and S.
5. The oligonucleotide according to any of claim 1 or 2, wherein R corresponds to a methylene carbonate group of formula -CH2-O-C(O) ORx wherein Rx is selected from optionally substituted alkyl cycloalkyl and (hetero)aryl groups.
6. The oligonucleotide according to any of claim 2 to 5, wherein Rx is selected from lower alkyl or cycloalkyl (C1-C7), phenyl including substituted phenyl and naphthyl groups.
7. The oligonucleotide according to anyone of claims 1 to 6, which comprises from 2 to 30 nucleotides.
8. The oligonucleotide according to anyone of claims 1 to 6 which contains nucleosides selected from ribonucleosides, 2'-deoxyribonucleosides, T- substituted ribonucleosides, 2'-4'-locked-ribonucleosides, 3'-amino- ribonucleosides, 3 '-amino-2'-deoxyribonucleosides.
9. The oligonucleotide according to anyone of claims 1 to 8, as a prodrug.
10. A method for producing a second oligonucleotide having at least one thiophosphate linkage, which comprises (a) providing a first oligonucleotide according to anyone of claims 1 to 8 and (b) cleaving at least one R group, from said first oligonucleotide to produce said second oligonucleotide having at least one phosphorothioate linkage.
11. The method according to claim 10, wherein the R group, is cleaved by reacting the first oligonucleotide in solution with a base chosen preferably from alkyl, cycloalkyl and aromatic amines, more preferably from primary or secondary alkyl amines, most preferably from n-propyl and tert-butyl amine.
12. The method according to claim 10 wherein the base is a hindered primary amine.
13. The method according to anyone of claims 10 to 12 wherein the cleavage is carried out in the presence of a sterically hindered base and of an activator which is generally a N-heteroaromatic base.
14. The method according to claim 24 wherein the first base is an alkyl primary amine wherein alkyl group bears identical or different substituents selected from Cl to C20 linear or branched alkyls. The method according to claim 24 wherein the first base is an aryl primary amine wherein aryl group contains linear or branched alkyl or aryl groups at 2 and/or 6 positions.
15. The method according to claim 24 or 25 wherein the activator is 1,2,4- triazole or other triazole and tetrazole derivatives.
16. A method for deprotecting an oligonucleotide according to any of claims 24 to 26 wherein the sterically hindered base is tert-butyl amine.
17. A method according to anyone of claim 9 to 16, further comprising purifying said second oligonucleotide having at least one thiophosphate linkage.
18. The method according to claim 17 which comprises at least precipitating the second oligonucleotide.
19. The method according to claim 17 or 18, further comprising extracting the second oligonucleotide with a solvent.
20. The method according to claim 18 or 19 which comprises dissolving the second oligonucleotide in a polar organic solvent preferably selected from methylene chloride, chloroform, acetonitrile, acetone and pyridine.
21. The method according to claim 20, wherein a solvent volume is used ranging from about 0.5 (n+1) mL to about 2.0 (n+1) mL, preferably, about 1.0 (n+1) mL, where n is the millimoles number of phosphorothioate triester linkages.
22. The method according to claim 20 or 21 wherein the solution of the second oligonucleotide is treated with a non-polar organic solvent preferably selected from hydrocarbons, ether solvent and their mixtures until the solution becomes turbid.
23. The method according to claim 22, wherein a solvent volume is used ranging from about l(n+l) mL to about 4(n+l) mL, preferably, about 2.0 (n+1) mL, where n is the millimoles number of phosphorothioate triester linkages,
24. The method according to claim 22 or 23 wherein the turbid solution is treated with a precipitation aid.
25. The method according to claim 23 where the precipitation aid is selected from among inert porous solids preferably selected from Celite, charcoal, wood cellulose and chromatography stationary phases such as silica or alumina.
26. The method according to claim 24 or 25 wherein the precipitation aid is used in an amount ranging from about 0.25 (n+1) g to about 1.5 (n+1) g, preferably, about 0.75 (n+1) g, where n is the millimoles number of phosphorothioate triester linkages.
27. The method according to claim 25 wherein after adding the precipitation aid the mixture is a treated with a second fraction of a non-polar organic solvent with volume of said fraction generally ranging from about l(n+l) mL to about 4(n+l) mL, preferably, about 2.0 (n+1) mL, wherein n is the millimoles number of phosphorothioate triester linkages.
28. The method according to anyone of claims 24 to 27 wherein the solid materials obtained in the precipitation step are filtered off and washed.
29. The method according to anyone of claims 18 to 28 wherein the oligonucleotide is extracted from the oligonucleotide-containing precipitate with a solvent.
30. The method according to claim 29 wherein the solvent comprises a mixture of polar organic solvent, preferably selected from acetonitrile, acetone, THF, DMF, DMSO and pyridine, with an aqueous medium, preferably water and wherein the volume ratio polar organic solvent/aqueous medium is preferably from about 0.5 to about 1.5, more preferably about 0.7.
31. The method according to claim 10, wherein the R group, preferably selected from the methyleneacyloxy group, the methylene carbamate group or the methylene carbonate group is cleaved in the human body or in the body of an animal.
32.A sulfurizing agent of formula R"-S-R wherein R corresponds to the formula (I)
Figure imgf000042_0001
wherein A is a geminally substituted alkylene group, preferably CH2, X and Y are independently selected from S and O, and Ro is selected from the group consisting of optionally substituted alkyl or aryl, SRx, ORx and NRxRy wherein Rx and Ry are selected from H and organic residues and at least Rx is a substituent other than H.
33. The sulfurizing agent according to claim 32 wherein R is selected from a methyleneacyloxy group, a methylene carbamate group or a methylene carbonate group and R" is a leaving group.
34. The sulfurizing agent according to any of claims 32 or 33 wherein R is as described in any of claims 1 to 6.
35. The sulfurizing agent of any of claims 32 to 34 which corresponds to formula (II)
O RA
wherein R and R are equal or different from each other and at least one of R aanndd RRB iiss sseelleecctteedd ffrroomm ssuubbssttiittuutteedd ssuullffoonnyyll oorr aa(cyl group, said RA and RB optionally forming together a cyclic substituent.
36. The sulfurizing agent according to any of claims 32 to 35 wherein R" is a sulfonamide group, preferably an N-substituted-N-alkylsulfonyl.
37. The sulfurizing agent of claim 36 which corresponds to formula (III)
O R4
° ° wherein Ri, R3 and R4 are independently a C1-C20, optionally unsaturated or aromatic, hydrocarbon residue, preferably a linear or branched alkyl group or a cycloalkyl group.
38. The sulfurizing agent according to any of claims 32 to 35 wherein R" is a dicarboxylamide.
39. The sulfurizing agent of claim 38 which corresponds to formula (IV)
Figure imgf000043_0001
wherein Z is an group, chosen among the group of -CH2-CH2- ,
-CH=CH-, -CH2-O-CH2- , ^
Figure imgf000043_0002
^ , preferably Z is a group.
40. A method for synthesizing an oligonucleotide which comprises using the sulfurizing agent according to anyone of claims 32 to 39 for sulfurizing at least one phosphorus internucleotide linkage of a precursor of said oligonucleotide.
41. The method according to claim 40,wherein the phosphorus internucleotide linkage is an H-phosphonate diester bond.
42. The method according to claim 41, which further comprises forming the H-phosphonate diester bond by coupling an H-phosphonate monoester salt with a protected nucleoside or oligonucleotide having a free hydroxy group.
43. The method according to claim 41 or 42, wherein the coupling is carried out in solution phase.
44. A process for the synthesis of a sulfurizing agent as described in any of claims 32 to 37, which comprises (a) reacting a sulfuryl halide, preferably sulfuryl chloride with a thioacetal of formula
R-S-C(O)-R2 wherein R is as described in claims 1 to 6 and R2 is an organic residue preferably selected from a C1-C20 optionally unsaturated or aromatic hydrocarbon residue residue to produce an intermediate product of formula R-S- W, wherein W is halogen preferably Cl and, (b) reacting said intermediate product with an N-sulfonyl compound or an N-acyl compound.
45. The process of claim 44 wherein the thioacetal is of formula Ri-C(O)- 0-CH2-S-C(O)-R2 wherein Ri and R2 are independently a C1-C20 optionally unsaturated or aromatic hydrocarbon residue and said thioacetal is reacted with sulfuryl chloride to produce an intermediate product of formula R1-C(O)-O-CH2- S-Cl, wherein Ri is independently a C1-C20, optionally unsaturated or aromatic, hydrocarbon residue.
46. The process according to claim 44 or 45 wherein in step (b) the intermediate is reacted with an N-sulfonyl compound of formula R3-S (O)2-NH- R4, wherein R3 and R4 are independently organic residues, preferably a C1-C20, optionally unsaturated or aromatic, hydrocarbon residue.
47. The process according to claim 44 or 45 wherein in step (b) the intermediate is reacted with an N-acyl compound of formula
HfH ° , wherein of -CH2-CH-
-CH=CH-, -CH2-O-CH2- ,
Figure imgf000045_0001
, preferably Z
Figure imgf000045_0002
48. The process according to any of claims 45 to 47, wherein Ri is selected from lower alkyl or cycloalkyl (C1-C7), phenyl including substituted phenyl and naphthyl groups, more preferably an ethyl group.
49. The process according to claim any of claims 44 to 47, wherein R2, R3 and R4 are selected from lower alkyl or cycloalkyl (C1-C7), phenyl including substituted phenyl and naphthyl groups, more preferably a methyl group.
PCT/EP2009/067902 2008-12-23 2009-12-23 Sulfurizing reagents and their use for oligonucleotides synthesis WO2010072831A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN2009801552887A CN102307889A (en) 2008-12-23 2009-12-23 Sulfurizing reagents and their use for oligonucleotides synthesis
CA2747999A CA2747999A1 (en) 2008-12-23 2009-12-23 Sulfurizing reagents and their use for oligonucleotides synthesis
JP2011542834A JP2012513450A (en) 2008-12-23 2009-12-23 Sulfurizing agents and their use to synthesize oligonucleotides
EP09799643A EP2382227A1 (en) 2008-12-23 2009-12-23 Sulfurizing reagents and their use for oligonucleotides synthesis
US13/165,918 US20120071640A1 (en) 2008-12-23 2011-06-22 Sulfurizing reagents and their use for oligonucleotides synthesis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14039108P 2008-12-23 2008-12-23
US61/140,391 2008-12-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/165,918 Continuation-In-Part US20120071640A1 (en) 2008-12-23 2011-06-22 Sulfurizing reagents and their use for oligonucleotides synthesis

Publications (1)

Publication Number Publication Date
WO2010072831A1 true WO2010072831A1 (en) 2010-07-01

Family

ID=41665222

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/067902 WO2010072831A1 (en) 2008-12-23 2009-12-23 Sulfurizing reagents and their use for oligonucleotides synthesis

Country Status (6)

Country Link
EP (1) EP2382227A1 (en)
JP (1) JP2012513450A (en)
KR (1) KR20110099333A (en)
CN (1) CN102307889A (en)
CA (1) CA2747999A1 (en)
WO (1) WO2010072831A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012001126A1 (en) * 2010-06-30 2012-01-05 Girindus America, Inc. A new method of using n-thio compounds for oligonucleotide synthesis
GB2471806B (en) * 2008-04-03 2012-12-19 Spring Bank Pharmaceuticals Inc Compositions and methods for treating viral infections
WO2013017469A1 (en) * 2011-07-29 2013-02-07 Girindus America, Inc. Sulfurization reagents on solid supports
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
WO2015107425A2 (en) 2014-01-16 2015-07-23 Wave Life Sciences Pte. Ltd. Chiral design
US9394333B2 (en) 2008-12-02 2016-07-19 Wave Life Sciences Japan Method for the synthesis of phosphorus atom modified nucleic acids
US9598458B2 (en) 2012-07-13 2017-03-21 Wave Life Sciences Japan, Inc. Asymmetric auxiliary group
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
US9617547B2 (en) 2012-07-13 2017-04-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
US9744183B2 (en) 2009-07-06 2017-08-29 Wave Life Sciences Ltd. Nucleic acid prodrugs and methods of use thereof
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016117663A1 (en) * 2015-01-21 2016-07-28 味の素株式会社 Precipitation accelerator and precipitation method in which same is used
CN106045887B (en) * 2016-06-28 2018-08-31 江苏之江化工有限公司 A kind of synthetic method of N- ethyls sulfenamide compound
CN115703727A (en) * 2021-08-05 2023-02-17 四川大学 Hydrogen peroxide prodrug and pharmaceutical application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3034951A (en) * 1960-08-04 1962-05-15 Stauffer Chemical Co S-[o, o-dialkylphosphorothiomethyl]-s'-alkyltrithiocarbonates and their methods of preparation and use as pesticides
DE2206678A1 (en) * 1972-02-11 1973-08-16 Bayer Ag 0-ALKYL-S- SQUARE CLIP ON CARBAMOYLOXYMETHYL SQUARE CLAMP FOR - (THIONO) THIOLPHOSPHORUS (PHOSPHONE) ACID EST, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS INSECTICIDES AND ACARICIDES
WO1998008809A1 (en) * 1996-08-30 1998-03-05 Hybridon, Inc. Novel sulfur transfer reagents for oligonucleotide synthesis
WO1998049181A1 (en) * 1997-04-30 1998-11-05 Hybridon, Inc. Novel sulfur transfer reagents for oligonucleotide synthesis
US6506894B1 (en) 1997-08-13 2003-01-14 Avecia Limited Solution phase synthesis of oligonucleotides
US20070149462A1 (en) * 2005-12-13 2007-06-28 Iyer Radhakrishnan P Nucleotide and oligonucleotide prodrugs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705099B1 (en) * 1993-05-12 1995-08-04 Centre Nat Rech Scient Phosphorothioate triester oligonucleotides and process for their preparation.
WO1996007392A2 (en) * 1994-09-07 1996-03-14 Hybridon, Inc. Oligonucleotide prodrugs
WO1998007734A1 (en) * 1996-08-21 1998-02-26 Hybridon, Inc. Oligonucleotide prodrugs

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3034951A (en) * 1960-08-04 1962-05-15 Stauffer Chemical Co S-[o, o-dialkylphosphorothiomethyl]-s'-alkyltrithiocarbonates and their methods of preparation and use as pesticides
DE2206678A1 (en) * 1972-02-11 1973-08-16 Bayer Ag 0-ALKYL-S- SQUARE CLIP ON CARBAMOYLOXYMETHYL SQUARE CLAMP FOR - (THIONO) THIOLPHOSPHORUS (PHOSPHONE) ACID EST, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS INSECTICIDES AND ACARICIDES
WO1998008809A1 (en) * 1996-08-30 1998-03-05 Hybridon, Inc. Novel sulfur transfer reagents for oligonucleotide synthesis
WO1998049181A1 (en) * 1997-04-30 1998-11-05 Hybridon, Inc. Novel sulfur transfer reagents for oligonucleotide synthesis
US6506894B1 (en) 1997-08-13 2003-01-14 Avecia Limited Solution phase synthesis of oligonucleotides
US20070149462A1 (en) * 2005-12-13 2007-06-28 Iyer Radhakrishnan P Nucleotide and oligonucleotide prodrugs

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
DREEF ET AL., SYNLETT, 1990, pages 481 - 483
ECKSTEIN, ANTISENSE NUCLEIC ACID DRUG DEV., vol. 10, no. 2, 2000, pages 117 - 21
GRYAZNOV ET AL., NUCLEOSIDES NUCLEOTIDES NUCLEIC ACIDS, vol. 20, no. 4-7, 2001, pages 401 - 10
GRYAZNOV, BIOCHEM. BIOPHYS. ACTA, vol. 1489, no. 1, 1999, pages 131 - 40
HERBERT ET AL., ONCOGENE, vol. 21, no. 4, 2002, pages 638 - 42
IYER ET AL., J. ORG. CHEM., vol. 55, 1990, pages 4693 - 4699
NIELSEN, METHODS MOL. BIOL., vol. 208, 2002, pages 3 - 26
P. HERDEWIJN: "Methods in Molecular Biology", vol. 288, article "Oligonucleotide synthesis, methods and applications", pages: 51 - 63
PADMANABHAN S ET AL: "Anti-HBV nucleotide prodrug analogs: Synthesis, bioreversibility, and cytotoxicity studies", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 16, no. 6, 15 March 2006 (2006-03-15), pages 1491 - 1494, XP025107033, ISSN: 0960-894X, [retrieved on 20060315] *
PETERSEN, WENGEL, TRENDS BIOTECHNOL., vol. 21, no. 2, 2003, pages 74 - 81
PRUZAN ET AL., NUCLEIC ACIDS RES., vol. 30, no. 2, 2002, pages 559 - 68
THIVIYANATHAN ET AL., BIOCHEMISTRY, vol. 41, no. 3, 2002, pages 827 - 38
TOSQUELLAS G ET AL: "The prooligonucleotide approach IV: Synthesis of chimeric prooligonucleotides with 6 enzymolabile masking groups and unexpected desulfurization side reaction", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 7, no. 3, 4 February 1997 (1997-02-04), pages 263 - 268, XP004136006, ISSN: 0960-894X *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2471806B (en) * 2008-04-03 2012-12-19 Spring Bank Pharmaceuticals Inc Compositions and methods for treating viral infections
US9394333B2 (en) 2008-12-02 2016-07-19 Wave Life Sciences Japan Method for the synthesis of phosphorus atom modified nucleic acids
US10329318B2 (en) 2008-12-02 2019-06-25 Wave Life Sciences Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
US9695211B2 (en) 2008-12-02 2017-07-04 Wave Life Sciences Japan, Inc. Method for the synthesis of phosphorus atom modified nucleic acids
US10307434B2 (en) 2009-07-06 2019-06-04 Wave Life Sciences Ltd. Nucleic acid prodrugs and methods of use thereof
US9744183B2 (en) 2009-07-06 2017-08-29 Wave Life Sciences Ltd. Nucleic acid prodrugs and methods of use thereof
US8710210B2 (en) 2010-06-30 2014-04-29 Girindus America, Inc. Method of using N-thio compounds for oligonucleotide synthesis
WO2012001126A1 (en) * 2010-06-30 2012-01-05 Girindus America, Inc. A new method of using n-thio compounds for oligonucleotide synthesis
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
US10280192B2 (en) 2011-07-19 2019-05-07 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
WO2013017469A1 (en) * 2011-07-29 2013-02-07 Girindus America, Inc. Sulfurization reagents on solid supports
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
US10167309B2 (en) 2012-07-13 2019-01-01 Wave Life Sciences Ltd. Asymmetric auxiliary group
US9982257B2 (en) 2012-07-13 2018-05-29 Wave Life Sciences Ltd. Chiral control
US9617547B2 (en) 2012-07-13 2017-04-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
US9598458B2 (en) 2012-07-13 2017-03-21 Wave Life Sciences Japan, Inc. Asymmetric auxiliary group
US10590413B2 (en) 2012-07-13 2020-03-17 Wave Life Sciences Ltd. Chiral control
EP4219516A2 (en) 2012-07-13 2023-08-02 Wave Life Sciences Ltd. Chiral control
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
US10160969B2 (en) 2014-01-16 2018-12-25 Wave Life Sciences Ltd. Chiral design
WO2015107425A2 (en) 2014-01-16 2015-07-23 Wave Life Sciences Pte. Ltd. Chiral design
EP4137572A1 (en) 2014-01-16 2023-02-22 Wave Life Sciences Ltd. Chiral design

Also Published As

Publication number Publication date
EP2382227A1 (en) 2011-11-02
CN102307889A (en) 2012-01-04
JP2012513450A (en) 2012-06-14
CA2747999A1 (en) 2010-07-01
KR20110099333A (en) 2011-09-07

Similar Documents

Publication Publication Date Title
WO2010072831A1 (en) Sulfurizing reagents and their use for oligonucleotides synthesis
JP7484951B2 (en) Methods for Producing Oligonucleotides
WO1998039349A1 (en) Protecting group for synthesizing oligonucleotide analogs
JP2003511386A (en) Compounds for protecting hydroxyl groups and methods of using the same
US6809195B1 (en) Process for the preparation of oligonucleotides
EP1995253B1 (en) Method for detaching protecting group on nucleic acid
EP1272501A1 (en) Process for the preparation of phosphorothioate triesters
AU2001235766A1 (en) Process for the preparation of phosphorothioate triesters
EP2588487B1 (en) A new method of using n-thio compounds for oligonucleotide synthesis
EP1317466B1 (en) Synthons for oligonucleotide synthesis
US20120071640A1 (en) Sulfurizing reagents and their use for oligonucleotides synthesis
US20190015439A1 (en) Dinucleotides
CA2659703C (en) Method for introducing a nucleic-acid-protecting group
KR100393913B1 (en) Method for producing di 4-thiadiene from 5-methyluridine
WO2013017469A1 (en) Sulfurization reagents on solid supports
EP0378941A2 (en) 2-Deoxyribonucleoside derivatives and their use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980155288.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09799643

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2747999

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2011542834

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 4848/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009799643

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20117017343

Country of ref document: KR

Kind code of ref document: A